Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A smooth, solid or cystic fibroepithelial (FIBROEPITHELIAL NEOPLASMS) tumor, usually found in the OVARIES but can also be found in the adnexal region and the KIDNEYS. It consists of a fibrous stroma with nests of epithelial cells that sometimes resemble the transitional cells lining the urinary bladder. Brenner tumors generally are benign and asymptomatic. Malignant Brenner tumors have been reported.
A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.
A sex cord-gonadal stromal tumor consists of LEYDIG CELLS; SERTOLI CELLS; and FIBROBLASTS in varying proportions and degree of differentiation. Most such tumors produce ANDROGENS in the Leydig cells, formerly known as androblastoma or arrhenoblastoma. Androblastomas occur in the TESTIS or the OVARY causing precocious masculinization in the males, and defeminization, or virilization (VIRILISM) in the females. In some cases, the Sertoli cells produce ESTROGENS.
A gonadal stromal neoplasm composed only of THECA CELLS, occurring mostly in the postmenopausal OVARY. It is filled with lipid-containing spindle cells and produces ESTROGENS that can lead to ENDOMETRIAL HYPERPLASIA; UTERINE HEMORRHAGE; or other malignancies in postmenopausal women and sexual precocity in girls. When tumors containing theca cells also contain FIBROBLASTS, they are identified as thecoma-fibroma tumors with less active hormone production.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. It is the counterpart of the classical seminoma of the testis, to which it is both grossly and histologically identical. Dysgerminomas comprise 16% of all germ cell tumors but are rare before the age of 10, although nearly 50% occur before the age of 20. They are generally considered of low-grade malignancy but may spread if the tumor extends through its capsule and involves lymph nodes or blood vessels. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1646)
Gonadal neoplasm composed entirely of SERTOLI CELLS or may have a component of GRANULOSA CELLS. Some of the Sertoli cell tumors produce ESTROGEN or ANDROGENS, but seldom in sufficient quantity to cause clinical symptoms such as FEMINIZATION or masculinization (VIRILISM).
General term for CYSTS and cystic diseases of the OVARY.
A tumor consisting of displaced ectodermal structures along the lines of embryonic fusion, the wall being formed of epithelium-lined connective tissue, including skin appendages, and containing keratin, sebum, and hair. (Stedman, 25th ed)
Pathological processes of the OVARY.
Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A malignant epithelial tumor with a glandular organization.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Neoplasms composed of more than one type of neoplastic tissue.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the MANDIBLE.
Tumors or cancer of the BILE DUCTS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.

An improved method for the structural profiling of keratan sulfates: analysis of keratan sulfates from brain and ovarian tumors. (1/9962)

A previously developed method for the structural fingerprinting of keratan sulfates (Brown et al., Glycobiology, 5, 311-317, 1995) has been adapted for use with oligosaccharides fluorescently labeled with 2-aminobenzoic acid following keratanase II digestion. The oligosaccharides are separated by high-pH anion-exchange chromatography on a Dionex AS4A-SC column. This methodology permits quantitative analysis of labeled oligosaccharides which can be detected at the sub-nanogram ( approximately 100 fmol) level. Satisfactory calibration of this method can be achieved using commercial keratan sulfate standards. Keratan sulfates from porcine brain phosphocan and human ovarian tumors have been examined using this methodology, and their structural features are discussed.  (+info)

Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. (2/9962)

Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise.  (+info)

Cancer risk in close relatives of women with early-onset breast cancer--a population-based incidence study. (3/9962)

Inherited susceptibility to breast cancer is associated with an early onset and bilateral disease. The extent of familial risks has not, however, been fully assessed in population-based incidence studies. The purpose of the study was to quantify the risks for cancers of the breast, ovary and other sites of close relatives of women in whom breast cancer was diagnosed at an early age. Records collected between 1943 and 1990 at the Danish Cancer Registry were searched, and 2860 women were found in whom breast cancer was diagnosed before age 40. Population registers and parish records were used to identify 14 973 parents, siblings and offspring of these women. Cancer occurrence through to 31 December 1993 was determined within the Cancer Registry's files and compared with national incidence rates. Women with early-onset breast cancer were at a nearly fourfold increased risk of developing a new cancer later in life (268 observed vs. 68.9 expected). The excess risk was most evident for second cancer of the breast (181 vs. 24.5) and for ovarian cancer (20 vs. 3.3). For mothers and sisters, risks for cancers of the breast and ovary were significantly increased by two- to threefold. Bilateral breast cancer and breast-ovarian cancer were very strong predictors of familial risks, with one in four female relatives predicted to develop breast and/or ovarian cancer by age 75. Mothers had a slightly increased risk of colon cancer, but not endometrial cancer. The risk for breast cancer was also increased among fathers (standardized incidence ratio 2.5; 95% CI 0.5-7.4) and especially brothers (29; 7.7-74), although based on small numbers. The risk for prostatic cancer was unremarkable. In this large population-based survey, the first-degree relatives of women who developed breast cancer before age 40 were prone to ovarian cancer as well as male and female breast cancer, but not other tumours that may share susceptibility genes with breast cancer.  (+info)

Frequent silencing of the GPC3 gene in ovarian cancer cell lines. (4/9962)

GPC3 encodes a glypican integral membrane protein and is mutated in the Simpson-Golabi-Behmel syndrome. Simpson-Golabi-Behmel syndrome, an X-linked condition, is characterized by pre- and postnatal overgrowth as well as by various other abnormalities, including increased risk of embryonal tumors. The GPC3 gene is located at Xq26, a region frequently deleted in advanced ovarian cancers. To determine whether GPC3 is a tumor suppressor in ovarian neoplasia, we studied its expression and mutational status in 13 ovarian cancer cell lines. No mutations were found in GPC3, but its expression was lost in four (31%) of the cell lines analyzed. In an of the cases where GPC3 expression was lost, the GPC3 promoter was hypermethylated, as demonstrated by Southern analysis. Expression of GPC3 was restored by treatment of the cells with the demethylating agent 5-aza-2'-deoxycytidine. A colony-forming assay confirmed that ectopic GPC3 expression inhibited the growth of ovarian cancer cell lines. Our results show that GPC3, a gene involved in the control of organ growth, is frequently inactivated in a subset of ovarian cancers and suggest that it may function as a tumor suppressor in the ovary.  (+info)

Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. (5/9962)

The natural history of hereditary and BRCA1- and BRCA2-associated epithelial ovarian cancer may differ from that of sporadic disease. The purpose of this study was to compare the clinical characteristics of BRCA1- and BRCA2-associated hereditary ovarian cancer, hereditary ovarian cancer with no identified BRCA1/2 mutation, and ovarian cancer in population-based controls. BRCA1 and BRCA2 mutation testing was carried out on index cases from 119 families with site-specific epithelial ovarian cancer or breast-ovarian cancer. We estimated overall survival in 151 patients from 57 BRCA1 and BRCA2 mutation families and compared it with that in 119 patients from 62 families in which a BRCA1/2 mutation was not identified. We compared clinical outcome and data on tumor histopathology, grade, and stage. We also compared survival in familial epithelial ovarian cancer, whether or not a mutation was identified, with that of an age-matched set of population control cases. Overall survival at 5 years was 21% (95% confidence interval, 14-28) in cases from BRCA1 mutation families, 25% (8-42) in BRCA2 mutation families, and 19% (12-26) in families with no identified mutation (P = 0.91). Survival in familial ovarian cancer cases as a whole was significantly worse than for population controls (P = 0.005). In the familial cases, we found no differences in histopathological type, grade, or stage according to mutation status. Compared to population control cases, mucinous tumors occurred less frequently in the familial cases (2 versus 12%, P<0.001), and a greater proportion of the familial cases presented with advanced disease (83% stage III/IV versus 56%; P = 0.001). We have shown that survival in familial ovarian cancer cases is worse than that in sporadic cases, whether or not a BRCA1/2 mutation was identified, perhaps reflecting a difference in biology analogous to that observed in breast cancer.  (+info)

Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. (6/9962)

BACKGROUND: Studies of survival following breast and ovarian cancers in BRCA1 and/or BRCA2 mutation carriers have yielded conflicting results. We undertook an analysis of a community-based study of Ashkenazi Jews to investigate the effect of three founder mutations in BRCA1 and BRCA2 on survival among patients with breast or ovarian cancer. METHODS: We collected blood samples and questionnaire data from 5318 Ashkenazi Jewish volunteers. The blood samples were tested for 185delAG (two nucleotide deletion) and 5382insC (single nucleotide insertion) mutations in BRCA1 and the 6174delT (single nucleotide deletion) mutation in BRCA2. To estimate survival differences in the affected relatives according to their BRCA1 and/or BRCA2 mutation carrier status, we devised and applied a novel extension of the kin-cohort method. RESULTS: Fifty mutation carriers reported that 58 of their first-degree relatives had been diagnosed with breast cancer and 10 with ovarian cancer; 907 noncarriers reported 979 first-degree relatives with breast cancer and 116 with ovarian cancer. Kaplan-Meier estimates of median survival after breast cancer were 16 years (95% confidence interval [CI] = 11-40) in the relatives of carriers and 18 years (95% CI = 15-22) in the relatives of noncarriers, a difference that was not statistically significant (two-sided P = .87). There was also no difference in survival times among the 126 first-degree relatives with ovarian cancer. We found no survival difference between patients with breast or ovarian cancer who were inferred carriers of BRCA1 and/or BRCA2 mutations and noncarriers. CONCLUSIONS: Carriers of BRCA1 and BRCA2 mutations appeared to have neither better nor worse survival prognosis.  (+info)

In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. (7/9962)

Adenoviral vectors, encoding genes for cell surface antigens or receptors, have been used to induce their high level expression on tumor cells in vitro and in vivo. These induced antigens and receptors can then be targeted with radiolabeled antibodies or peptides for potential radiotherapeutic applications. The purpose of this study was to determine a dosing schema of an adenoviral vector encoding the human somatostatin receptor subtype 2 (AdCMVhSSTr2) for achieving the highest tumor localization of [(111)In]-DTPA-D-Phe1-octreotide, which binds to this receptor, in a human ovarian cancer model as a prelude to future therapy studies. AdCMVhSSTr2 was produced and used to induce hSSTr2 on A427 human nonsmall cell lung cancer cells and on SKOV3.ipl human ovarian cancer cells in vitro, as demonstrated by competitive binding assays using [125I]-Tyr1-somatostatin and [(111)In]-DTPA-D-Phe1-octreotide. Mice bearing i.p. SKOV3.ip1 tumors administered 1 x 10(9) plaque-forming units of AdCMVhSSTr2 i.p. 5 days after tumor cell inoculation, followed by an i.p. injection of [(111)In]-DTPA-D-Phe1-octreotide 2 days later, showed a range of 15.3-60.4% median injected dose/gram (ID/g) in tumor at 4 h after injection compared with 3.5% ID/g when [125I]-Tyr1-somatostatin was administered and 0.3% ID/g when the negative control peptide [125I]-mIP-bombesin was administered. Mice administered a control adenoviral vector encoding the gastrin-releasing peptide receptor did not have tumor localization of [(111)In]-DTPA-D-Phe1-octreotide (<1.6% ID/g), demonstrating specificity of [(111)In]-DTPA-D-Phe1-octreotide for the AdCMVhSSTr2 induced tumor cells. In another set of experiments, the tumor localization of [(111)In]-DTPA-D-Phe1-octreotide was not different 1, 2, or 4 days after AdCMVhSSTr2 injection (31.8, 37.7, and 40.7% ID/g, respectively; P = 0.88), indicating that multiple injections of radiolabeled peptide can be administered with equivalent uptake over a 4-day period. [(111)In]-DTPA-D-Phe1-octreotide tumor localization in animals administered AdCMVhSSTr2 on consecutive days or 2 days apart was 22.4% ID/g and 53.2% ID/g, respectively (P = 0.009) when [(111)In]-DTPA-D-Phe1-octreotide was given 1 day after the second AdCMVhSSTr2 injection. There was no difference in [(111)In]-DTPA-D-Phe1-octreotide localization after a single AdCMVhSSTr2 injection (40.7% ID/g) or two injections of AdCMVhSSTr2 given 1 (45.9% ID/g) or 2 (53.2% ID/g) days apart, where [(111)In]-DTPA-D-Phe1-octreotide was given in each case 4 days after the first AdCMVhSSTr2 injection (P = 0.65). Therefore, two AdCMVhSSTr2 injections did not increase [(111)In]-DTPA-D-Phe1-octreotide tumor localization compared with one injection, which eliminates concerns about an immune response to a second dose of AdCMVhSSTr2. This will be the basis for a therapeutic protocol with multiple administrations of an octreotide analogue labeled with a therapeutic radioisotope.  (+info)

Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. (8/9962)

Theanine is a peculiar amino acid existing in green tea leaves, which was previously indicated to enhance the antitumor activity of doxorubicin. In the present study, the effect of combination of theanine with doxorubicin against hepatic metastasis of M5076 ovarian sarcoma was investigated. The primary tumor was significantly reduced by the combined treatment on M5076 transplanted (s.c.) mice. The liver weight of control mice increased to twice the normal level because of hepatic metastasis of M5076. In contrast, the injection of doxorubicin alone or theanine plus doxorubicin suppressed the increase in liver weight and inhibited hepatic metastasis. Moreover, the liver weights and metastasis scores demonstrated that theanine enhanced the inhibition of hepatic metastasis induced by doxorubicin. Furthermore, in vitro experiments indicated that theanine increased the intracellular concentration of doxorubicin remaining in M5076 cells. This action suggests that theanine leads the enhancement of the suppressive efficacy of doxorubicin on hepatic metastasis in vivo. Therefore, it was proved that theanine increased not only the antitumor activity on primary tumor but also the metastasis-suppressive efficacy of doxorubicin. The effect of theanine on the efficacy of antitumor agents is expected to be applicable in clinical cancer chemotherapy.  (+info)

TY - JOUR. T1 - Race/ethnic variations in ovarian cancer mortality in the United States, 1992-1997. AU - Howe, Holly L.. AU - Tung, Ko Hui. AU - Coughlin, Steven. AU - Jean-Baptiste, Rachel. AU - Hotes, Joellyn. PY - 2003/5/15. Y1 - 2003/5/15. N2 - Ovarian cancer is reported to be the most fatal malignancy of the female genital tract and the fifth leading cause of cancer deaths among women. In the current study, the authors describe ovarian cancer mortality by race and ethnicity in the U.S. during the years 1992-1997, a period comparable to the ovarian cancer incidence data presented in this supplement.. AB - Ovarian cancer is reported to be the most fatal malignancy of the female genital tract and the fifth leading cause of cancer deaths among women. In the current study, the authors describe ovarian cancer mortality by race and ethnicity in the U.S. during the years 1992-1997, a period comparable to the ovarian cancer incidence data presented in this supplement.. UR - ...
TY - JOUR. T1 - Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development. AU - Zannoni, Gian Franco. PY - 2020. Y1 - 2020. N2 - Epithelial ovarian cancer (EOC), the deadliest among gynecologic malignancies, is ranked as the fifth leading cause of cancer deaths in females [1]. Based on morphological findings, cellular origins, clinical characteristics, and several molecular genetic/epigenetic alterations, EOC has been subdivided into five main types: high-grade serous (HGSC, 70%), endometrioid (EC, 10%), clear cell (CC, 10%), mucinous (MC, 3%), and low-grade serous carcinomas (LGSC, , 5%) that account for over 95% of cases [2]. HGSCs generally harbor TP53 alterations, a pronounced genomic instability and, also, inherited and somatic BRCA1 and BRCA2 mutations. The other abovementioned cancer types are frequently characterized by mutations in KRAS, BRAF, PTEN, and CTNNB1 (Beta-catenin), and a relatively stable karyotype [2]. In this complex and heterogeneous ...
Get Ovarian Cancer Treatment cost from certified hospitals in Kolkata. Get assistance from medical experts to select best hospital for Ovarian Cancer Treatment in Kolkata
TY - JOUR. T1 - Adenosine triphosphate-based chemotherapy response assay predicts long-Term survival of primary epithelial ovarian cancer. AU - Li, Lan Ying. AU - Kim, Sang Wun. AU - Nam, Eun Ji. AU - Lee, Jungyun. AU - Kim, Sunghoon. AU - Kim, Young Tae. PY - 2019/2/1. Y1 - 2019/2/1. N2 - Objective The aim of this study is to analyze the long-Term relapse-free survival and overall survival outcomes of primary ovarian cancer patients using adenosine triphosphate-based chemotherapy response analysis. Methods In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed. Chemosensitivity with single or combined three agents and clinical characteristics of patients were studied to understand their correlation with long-Term relapse-free survival and overall survival. ...
While ovarian cancer remains the most lethal gynecological malignancy in the United States, there are no biomarkers available that are able to predict therapeutic responses to ovarian malignancies. OVCAR3 cells were treated with EGF1, and the time course of cell progression was monitored based on Akt phosphorylation and growth dynamics. EGF-stimulated Akt phosphorylation was detected at 12 h post-treatment, but an impact on expansion was not really noticed until 48 l post-exposure. Growth-stimulated mobile lysates had been examined for proteins single profiles between treatment organizations and across period factors using iTRAQ marking and mass spectrometry. The proteins response to EGF treatment was determined via iTRAQ evaluation in EGF-stimulated lysates relatives to vehicle-treated individuals across the treatment period program. Approval research had been performed on one of the controlled aminoacids differentially, lysosomal-associated membrane layer INK 128 proteins 1 (Light-1), in human ...
Olaparib (PARP inhibitors) - Ovarian Cancer Treatment Olaparib (PARP inhibitors) - Ovarian Cancer Treatment Olaparib (PARP inhibitors) - Ovarian Cancer
Fingerprint Dive into the research topics of Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Together they form a unique fingerprint. ...
TY - JOUR. T1 - Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer. T2 - A report from the ovarian cancer association consortium. AU - Amankwah, Ernest K.. AU - Wang, Qinggang. AU - Schildkraut, Joellen M.. AU - Tsai, Ya Yu. AU - Ramus, Susan J.. AU - Fridley, Brooke L.. AU - Beesley, Jonathan. AU - Johnatty, Sharon E.. AU - Webb, Penelope M.. AU - Chenevix-Trench, Georgia. AU - Australian Ovarian Cancer Study Group, Ovarian Cancer Study Group. AU - Dale, Laura C.. AU - Lambrechts, Diether. AU - Amant, Frederic. AU - Despierre, Evelyn. AU - Vergote, Ignace. AU - Gayther, Simon A.. AU - Gentry-Maharaj, Aleksandra. AU - Menon, Usha. AU - Chang-Claude, Jenny. AU - Wang-Gohrke, Shan. AU - Anton-Culver, Hoda. AU - Ziogas, Argyrios. AU - Dörk, Thilo. AU - Dürst, Matthias. AU - Antonenkova, Natalia. AU - Bogdanova, Natalia. AU - Brown, Robert. AU - Flanagan, James M.. AU - Kaye, Stanley B.. AU - Paul, James. AU - Bützow, Ralf. AU - Nevanlinna, Heli. AU - Campbell, ...
Cell lines and culture. The derivation, source, and propagation of human epithelial ovarian cancer cell lines, such as cisplatin-sensitive (A2780-PAR) and platinum-resistant (A2780-CP20 and RMG2) epithelial ovarian cancer cell lines, were maintained as previously described (30). The A2780-CP20 cell line was developed by sequential exposure of the A2780 cell line to increasing concentrations of cisplatin. All experiments were done with 70% to 80% confluent cultures.. ATP7A and ATP7B gene silencing by siRNA. siRNA constructs targeted to ATP7A and ATP7B were designed and purchased from Qiagen. The target sequences were 5′-CTGGACCGGATTGTTAATTAT-3′ (for ATP7A) and 5′-CCAATTGATATTGAGCGGTTA-3′ (for ATP7B). In vitro transient transfection was done as described previously (28). Briefly, cells were transfected with ATP7A- and/or ATP7B-specific or scrambled (control) siRNA using RNAiFect reagent (Qiagen). At selected time intervals, cells were harvested to measure mRNA and protein levels of ATP7B ...
Xu, J., et al. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues. The International Journal of Biochemistry & Cell Biology. S1357-2725(18)30258-9. 10/12/2018.. We identified 634 differentially expressed peptides, 508 of these peptides were highly abundant in serous ovarian cancer tissues, a result consistent with higher protease activity in ovarian cancer patients. The difference in preferred cleavage sites between the serous ovarian cancer tissues and normal ovarian epithelium indicates the characteristic peptidome of ovarian cancer and the nature of cancer-associated protease activity. Interestingly, KEGG pathway analysis of the peptide precursors indicated that the differentially regulated pathways in ovarian cancer are highly consistent with the pathways discovered in other cancers. Besides, we found that a proportion of the differentially expressed peptides are similar to the known immune-regulatory peptides and anti-bacterial peptides. Then we further ...
Vectors based on adenoviruses have been designed as targeted anti-cancer therapeutics that showed promising results in pre-clinical applications. In clinical trials, these oncolytic adenoviruses have generally been proved safe in patients, but have fallen short of their expected therapeutic value. In this thesis the susceptibility of primary ovarian cancer cells to oncolytic adenoviruses was studied in order to identify cellular mechanisms that confer resistance to virotherapy. Using gene expression profiling of cancer cells either resistant or susceptible to viral oncolysis, it was discovered that the epithelial phenotype of ovarian cancer represents a barrier to infection by commonly used oncolytic adenoviruses targeted to coxsackie- and adenovirus receptor (CAR) or CD46. Accessibility to viral receptors was critically linked to depolarization and the loss of tight and adherens junctions, both hallmarks of epithelial-mesenchymal transition (EMT). Importantly, tumors in situ as well as ...
We have previously demonstrated that Kruppel-like factor 8 (KLF8) participates in oncogenic transformation of mouse fibroblasts and is highly overexpressed in human ovarian cancer. In this work, we first correlated KLF8 overexpression with the aggressiveness of ovarian patient tumors and then tested if KLF8 could transform human ovarian epithelial cells. Using the immortalized non-tumorigenic human ovarian surface epithelial cell line T80 and retroviral infection, we generated cell lines that constitutively overexpress KLF8 alone or its combination with the known ovarian oncogenes c-Myc, Stat3c and/or Akt and examined the cell lines for anchorage-independent growth and tumorigenesis. The soft agar clonogenic assay showed that T80/KLF8 cells formed significantly more colonies than the mock cells. Interestingly, the cells expressing both KLF8 and c-Myc formed the largest amounts of colonies, greater than the sum of colonies formed by the cells expressing KLF8 and c-Myc alone. These results suggested that
Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
DISEASE CHARACTERISTICS: Histologically confirmed stage III ovarian epithelial cancer or primary peritoneal carcinoma of one of the following cell types: Serous adenocarcinoma Mucinous adenocarcinoma Clear-cell adenocarcinoma Endometrioid Adenocarcinoma (not otherwise specified) Undifferentiated carcinoma Transitional cell Malignant Brenners tumor Mixed epithelial carcinoma No borderline tumor (tumor of low malignant potential) Underwent prior standard initial cytoreductive surgery within the past 6 weeks Optimally resected disease with no residual site of disease more than 1 cm in greatest dimension Removal of all disease extending beyond the reproductive tract Total hysterectomy and bilateral salpingo-oopherectomy at cytoreductive surgery or in the past. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no ...
A DNA repair pathway-focused score has the potential to help determine if first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients, according to a study published April 13 in the Journal of the National Cancer Institute.. Most ovarian cancer patients are diagnosed with advanced disease (stages III and IV). They undergo surgery to remove as much tumor as possible, and then undergo platinum-based chemotherapy. But tools to predict response to platinum-based chemotherapy in ovarian cancer patients have been inadequate.. In order to determine if a DNA repair pathway-focused score could help predict outcomes for ovarian cancer patients treated with platinum-based chemotherapy, Josephine Kang, M.D., Ph.D., of the Department of Radiation Oncology at Dana Farber Cancer Institute, and colleagues gathered gene expression data from The Cancer Genome Atlas (TCGA) database for patients with advanced stage ovarian cancer, and established a molecular score by looking at the ...
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum ...
The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease. In this study, we defined AXL as a therapeutic target for metastatic ovarian cancer. AXL is primarily expressed in metastases and advanced-stage human ovarian tumors but not in normal ovarian epithelium. Genetic inhibition of AXL in human metastatic ovarian tumor cells is sufficient to prevent the initiation of metastatic disease in vivo. Mechanistically, inhibition of AXL signaling in animals with metastatic disease results in decreased invasion and matrix metalloproteinase activity. Most importantly, soluble human AXL receptors that imposed a specific blockade of the GAS6/AXL pathway had a profound inhibitory effect on progression of established metastatic ovarian cancer without normal tissue toxicity. These results offer the first genetic validation of GAS6/AXL targeting as an effective strategy for inhibition of
TY - JOUR. T1 - Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer. AU - Sakuma, Michiko. AU - Akahira, Jun Ichi. AU - Suzuki, Takashi. AU - Inoue, Satoshi. AU - Ito, Kiyoshi. AU - Moriya, Takuya. AU - Sasano, Hironobu. AU - Okamura, Kunihiro. AU - Yaegashi, Nobuo. N1 - Funding Information: This work was supported in part by a grant-in-aid for Scientific Research from the Ministry of Health and Welfare, a grant-in-aid from the Ministry of Education, Science and Culture, a grant-in-aid from Kurokawa Cancer Research Foundation, a grant-in-aid from Japan Gynecologic Oncology Group (JGOG) and the 21st Century Center of Excellence (COE) Program Special Research Grant from the Ministry of Education Science, Sports and Culture.. PY - 2005/12. Y1 - 2005/12. N2 - Objective. The estrogen-responsive ring finger protein (Efp) gene, one of estrogen receptor (ER) target genes, is considered to be essential for estrogen-dependent cell ...
TY - JOUR. T1 - A single nucleotide polymorphism in catalase is strongly associated with ovarian cancer survival. AU - Belotte, Jimmy. AU - Fletcher, Nicole M.. AU - Saed, Mohammed G.. AU - Abusamaan, Mohammed S.. AU - Dyson, Gregory. AU - Diamond, Michael P.. AU - Saed, Ghassan M.. PY - 2015/8/24. Y1 - 2015/8/24. N2 - Ovarian cancer is the deadliest of all gynecologic cancers. Recent evidence demonstrates an association between enzymatic activity altering single nucleotide polymorphisms (SNP) with human cancer susceptibility. We sought to evaluate the association of SNPs in key oxidant and antioxidant enzymes with increased risk and survival in epithelial ovarian cancer. Individuals (n = 143) recruited were divided into controls, (n = 94): healthy volunteers, (n = 18), high-risk BRCA1/2 negative (n = 53), high-risk BRCA1/2 positive (n = 23) and ovarian cancer cases (n = 49). DNA was subjected to TaqMan SNP genotype analysis for selected oxidant and antioxidant enzymes. Of the seven selected SNP ...
Younger women with early-stage ovarian cancer can keep the healthy ovary and uterus, according to the September 15, 2009, issue of Cancer....
MD Andersons physicians specialize in treating all types of ovarian cancer. Learn more about ovarian cancer treatment, surgery, chemotherapy and other options.
Epithelial ovarian cancer (EOC) is highly lethal gynecological cancer. Forkhead Box Protein C2 (FOXC2) promotes occurrence and development of various malignant tumors. The present study is aimed at exploring the correlation between the polymorphism of FOXC2 and epithelial ovarian cancer susceptibility in Chinese Han population. A case-control design was used to verify the association between FOXC2 polymorphisms and epithelial ovarian cancer. The genotyping was performed using Taqman® SNP Genotyping kit by qRT-PCR. The genetic variants including rs3751794 C | T, rs1035550 A | G, rs4843163 C | G and rs4843396 C | T in FOXC2 gene were analyzed. The strength of the associations was detected using odds ratios and 95% confidence intervals. Stratification analyses showed the association between the FOXC2 gene polymorphisms rs3751794 C | T, rs4843163 C | G and rs4843396 C | T with epithelial ovarian cancer susceptibility in terms of age, metastasis status, clinical stage, pathological grade, pregnant times,
The role of estrogen in the growth and survival of ovarian cancer cells is controversial. In this study, we investigated the changes in cell-cycle regulatory proteins in ovarian cancer cell lines after estrogen treatment to explore the role of estrog
Background Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine/threonine kinase that has an important function in cancers tumorigenesis and development. at both mRNA and proteins levels. Conclusion Used together, our outcomes demonstrate the fact that GSK-3 inhibitor AZD1080 suppresses ovarian cancers development and for that reason may indicate a fresh path for ovarian cancers treatment. strong course=kwd-title Keywords: ovarian cancers, GSK-3 inhibitor, AZD1080, tumorigenesis, development Introduction Ovarian cancers may be the third most common feminine reproductive system cancer tumor. The ovarian cancers mortality rate may be the highest from the gynecological malignancies because of the insufficient effective early diagnostic strategies, its chemotherapy level of resistance, and its capability to metastasize and recurrence. The 5-calendar year survival rate is certainly 30%, rendering it as a significant threat to medical and lives of females.1,2 Ovarian cancers has many ...
Cancer Monthly. Ovarian Cancer treatments. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Cancer Monthly. Ovarian Cancer treatments. Chemotherapy. Sloan-Kettering Cancer Center, New York, United States. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Ovarian cancer is a type of cancer that begins in a womens ovaries. Women have two ovaries that produce eggs as well as the hormones estrogen and progesterone. Ovarian cancer can be hard to diagnose because early-stages of ovarian cancer rarely cause any symptoms and advanced-stage ovarian cancer may cause few and nonspecific symptoms. The symptoms of ovarian cancer may include abdominal bloating, quickly feeling full when eating, weight loss, cramping in the lower stomach, changes in bowel habits, and a frequent need to urinate.. The cause of ovarian cancer is unclear. In general, cancer is caused by genetic mutations that turn normal cells into abnormal cancer cells that quickly multiply, forming a mass (tumor). The type of cell where the cancer begins determines the type of ovarian cancer. These types included epithelial tumor, stromal tumor, and germ cell tumor. Certain factors may increase your risk of ovarian cancer. These include age (most common in women ages 50 to 60), estrogen hormone ...
The distribution of genotypes for Arg399Gln XRCC1 polymorphism in ovarian cancers vs. controls was: 58.0% vs. 38.5% for Arg/Arg, 32.0% vs. 26.9% for Arg/Gln, and 10.0% vs. 34.6% for Gln/Gln genotype, respectively. We found that XRCC1 Arg allele is associated with ovarian cancer risk (OR= 2.635 for Arg vs. Gln with 95% CI of 1.526 to 4.550). The Arg allele exerts its effect on increased risk for ovarian cancer development in dominant model (Arg/Arg plus Arg/Gln vs. Gln/Gln) with OR (and 95 % CI) of 4.765 (1.692 to 13.414) as well as in recessive model (Arg/Arg vs. Arg/Gln plus Gln/Gln) with OR (and 95 % CI) of 2.210 (1.072 to 4.555). ...
At Minnesota Oncology, ovarian cancer treatment options are individualized according to the patients type and stage of cancer and also other factors.
Table of Contents. 1 Market Overview. 1.1 Ovarian Cancer Treatment Drugs Introduction. 1.2 Market Analysis by Type. 1.2.1 Platinum Anticancer Drugs. 1.2.2 Fluoropyrimidines. 1.2.3 Anthracycline Antibiotics. 1.2.4 Therapertic Antibody. 1.2.5 Small Molecules Drug. 1.2.6 Aromatase Inhibitors (Targeted Therapy Drug). 1.2.7 Anti-estrogens. 1.2.8 Aromatase Inhibitors (Endocrine Therapy Drug). 1.3 Market Analysis by Applications. 1.3.1 Hospital. 1.3.2 Clinic. 1.3.3 Drugstore. 1.4 Market Analysis by Regions. 1.4.1 North America (United States, Canada and Mexico). United States Market States and Outlook (2013-2023). Canada Market States and Outlook (2013-2023). Mexico Market States and Outlook (2013-2023). 1.4.2 Europe (Germany, France, UK, Russia and Italy). Germany Market States and Outlook (2013-2023). France Market States and Outlook (2013-2023). UK Market States and Outlook (2013-2023). Russia Market States and Outlook (2013-2023). ...
This study focuses on Chinas Ovarian Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed Chinas society and economy. China is one of the worlds major producers for industrial and consumer products. Far outpacing other economies in the world, China is the worlds fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market ...
TY - JOUR. T1 - Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. AU - Yemelyanova, A. V.. AU - Cosin, J. A.. AU - Bidus, M. A.. AU - Boice, C. R.. AU - Seidman, J. D.. PY - 2008/5/1. Y1 - 2008/5/1. N2 - The progression of ovarian carcinoma from stage I when it is confined to the ovaries and curable to disseminated abdominal disease, which is usually fatal, is poorly understood. An accurate understanding of this process is fundamental to designing, testing, and implementing an effective screening program for ovarian cancer. Pathologic features of the primary ovarian tumors in 41 FIGO stage I ovarian carcinomas were compared with those in 40 stage III carcinomas. The primary ovarian tumors in stage I cases, when compared with stage III, respectively, were significantly larger (15.4 versus 9.8 cm), were less frequently bilateral (12% versus 75%), more frequently contained a noninvasive component (88% versus 30%), had a higher proportion of a ...
The aim of the study was to investigate long-term trends in the incidence of borderline tumors and ovarian cancer in Sweden during 1960-2005, based on data from the population-based Swedish Cancer Register. We identified 6,288 patients with borderline ovarian tumors and a total of 34,977 cases of ovarian cancer during the study period. The age-standardized incidence of borderline ovarian tumors increased from 1.0 to 5.3 per 100,000 women-years from 1960-1964 to 2000-2005 and the incidence of ovarian cancer increased from 16.4 to 19.7 per 100,000 women-years from 1960-1964 to 1980-1989 and then declined to 16.6 per 100,000 women-years to the period 2000-2005. Borderline ovarian tumors comprised 15% of all primary ovarian neoplasms and the proportion increased from 8.3 to 23.6% during the study period. The median age at diagnosis for patients with borderline ovarian tumors and ovarian cancer was 55.2 and 61.6 years, respectively. In women younger than 40 years, 34% of all primary ovarian ...
Metastatic Ovarian Cancer-Pipeline Review, H2 2015. Summary. Global Markets Directs, Metastatic Ovarian Cancer-Pipeline Review, H2 2015, provides an overview of the Metastatic Ovarian Cancers therapeutic pipeline.. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC ...
TY - JOUR. T1 - Role of CSF-1 in progression of epithelial ovarian cancer. AU - Chambers, Setsuko K. PY - 2009. Y1 - 2009. N2 - Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and metastasis of ovarian cancer is key to development of targeted therapeutics. It is only in this way that therapeutic potential can be translated to reality. Here, we describe the evidence to date for the role of CSF-1/c-fms signaling in ovarian cancer invasiveness and metastasis, including the recent understanding of how CSF-1/c-fms expression is regulated with identification of significant post-transcriptional regulators.. AB - Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and ...
The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only superficially invasive. However, since the rapidly proliferating tumors compress visceral organs and are only temporarily chemosensitive, ovarian carcinoma is a deadly disease, with a cure rate of only 30%. There are a number of genetic and epigenetic changes that lead to ovarian carcinoma cell transformation. Ovarian carcinoma could originate from any of three potential sites: the surfaces of the ovary, the fallopian tube, or the mesothelium-lined peritoneal cavity. Ovarian cacinoma tumorigenesis then either progresses along a stepwise mutation process from a slow growing borderline tumor to a well-differentiated carcinoma (type I) or involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II). During initial tumorigenesis, ovarian carcinoma cells undergo an ...
(HealthDay)-Operative outcomes of laparoscopic approach in patients with early-stage ovarian cancer may be comparable with those of laparotomy, according to a meta-analysis published in the July issue of the American Journal ...
TY - JOUR. T1 - Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role. T2 - A Southwest Oncology Group ancillary study. AU - Hawes, Debra. AU - Liu, P. Y.. AU - Muggia, Franco M.. AU - Wilczynski, Sharon. AU - Cote, Richard. AU - Felix, Juan. AU - Terada, Keith. AU - Belt, Robert J.. AU - Alberts, David S. PY - 2002. Y1 - 2002. N2 - Objective. The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment. Methods. This study made use of samples from patients entered into a prospective randomized study of the Southwest Oncology Group (SWOG 8835) that treated patients with minimal residual disease at second-look laparotomy with ...
Title:PARP Inhibitors in Epithelial Ovarian Cancer. VOLUME: 13 ISSUE: 2. Author(s):Kristin N. Taylor and Ramez N. Eskander*. Affiliation:Rebecca and John Moores Cancer Center, Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, Rebecca and John Moores Cancer Center, Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA. Keywords:BRCA mutation, homologous recombination deficiency, PARP inhibitor, poly (ADP-ribose) polymerase, ovarian cancer, synthetic lethality.. Abstract:Background: Ovarian cancer remains the most common lethal gynecologic malignancy. The therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage disease remain limited, reflecting the need for novel therapies. Poly(ADP-ribose) polymerase (PARP) inhibitors have recently demonstrated a significant therapeutic effect in patients with recurrent, high grade serous ovarian ...
TY - JOUR. T1 - Ovarian cancer detection by DNA methylation in cervical scrapings. AU - Wu, Tzu I.. AU - Huang, Rui Lan. AU - Su, Po Hsuan. AU - Mao, Shih Peng. AU - Wu, Chen Hsuan. AU - Lai, Hung Cheng. PY - 2019/11/27. Y1 - 2019/11/27. N2 - Background: Ovarian cancer (OC) is the most lethal gynecological cancer, worldwide, largely due to its vague and nonspecific early stage symptoms, resulting in most tumors being found at advanced stages. Moreover, due to its relative rarity, there are currently no satisfactory methods for OC screening, which remains a controversial and cost-prohibitive issue. Here, we demonstrate that Papanicolaou test (Pap test) cervical scrapings, instead of blood, can reveal genetic/epigenetic information for OC detection, using specific and sensitive DNA methylation biomarkers. Results: We analyzed the methylomes of tissues (50 OC tissues versus 6 normal ovarian epithelia) and cervical scrapings (5 OC patients versus 10 normal controls), and integrated public methylomic ...
MicroRNAs (miRNAs) are small noncoding RNAs that have important roles in gene regulation. We have previously reported that activin receptor-like kinase 7 (ALK7) and its ligand, Nodal, induce apoptosis in human epithelial ovarian cancer cells. In this study, we examined the regulation of ALK7 by miRNAs and demonstrate that miR-376c targets ALK7. Ectopic expression of miR-376c significantly increased cell proliferation and survival, enhanced spheroid formation and blocked Nodal-induced apoptosis. Interestingly, overexpression of miR-376c blocked cisplatin-induced cell death, whereas anti-miR-376c enhanced the effect of cisplatin. These effects of miR-376c were partially compensated by the overexpression of ALK7. Moreover, in serous carcinoma samples taken from ovarian cancer patients who responded well to chemotherapy, strong ALK7 staining and low miR-376c expression was detected. By contrast, ALK7 expression was weak and miR-376c levels were high in samples from patients who responded poorly to ...
In this study a new low-grade serous ovarian carcinoma cell line, named as CAISMOV24, was characterized in terms of its in vitro cell growth, production of soluble biomarkers and expression of cell surface molecules. Additionally, CAISMOV24 was molecularly characterized and compared to its primary malignant cells for genomic alterations. In vitro models of well-characterized low-grade serous ovarian cell lines are currently limited in the literature. CAISMOV24 resulted from the in vitro spontaneous immortalization of primary malignant cells from ascites that was associated with a low-grade serous ovarian carcinoma. Although malignant cells of ovarian neoplasia from either tumor tissue or ascites can be cultivated in vitro for a limited period, only a minority of the primary cell cultures may become cell lines [14]. Spontaneous immortalization of primary cultures of malignant cells is an event occurring at a very low frequency. As an example, ODonnell et al. [11] reported the occurrence of only ...
Stage three ovarian cancer survival rate is somewhat high. Stage 3 is a serious level of ovarian cancer but life expectancy is still considered high. Abo
Research highlights: {yields} PPAR{gamma} ligands increased the rate of apoptosis and inhibition of proliferation in ovarian cancer cells. {yields} PPAR{gamma} ligands induced p63 and p73 expression, but not p53. {yields} p63 and p73 leads to an increase in p21 expression and apoptosis in ovarian cancer cells with treatment PPAR{gamma} ligands. {yields} These findings suggest that PPAR{gamma} ligands suppressed growth of ovarian cancer cells through upregulation of p63 and p73. -- Abstract: Peroxisome proliferator-activated receptor gamma (PPAR{gamma}) agonists, including thiazolidinediones (TZDs), can induce anti-proliferation, differentiation, and apoptosis in various cancer cell types. This study investigated the mechanism of the anticancer effect of TZDs on human ovarian cancer. Six human ovarian cancer cell lines (NIH:OVCAR3, SKOV3, SNU-251, SNU-8, SNU-840, and 2774) were treated with the TZD, which induced dose-dependent inhibition of cell growth. Additionally, these cell lines exhibited ...
Bisphenol A (BPA) is one of the most prevalent chemicals in many products used on a daily basis, making human exposure to it incredibly pervasive and raising concerns about its health consequences. One area of research focus has been the role of BPA exposure in promoting the development of ovarian cancer; however, the doses used in most of previous studies are relatively high and most likely exceed physiologically relevant levels. At the same time, few studies have described potential mechanisms underlying the link between BPA and increased cancer risk. To address these concerns, the authors investigated the mechanism(s) by which low concentrations of BPA promote proliferation and energy metabolism in the human ovarian cancer cell line OVCAR-3. The results showed that even sub-toxic BPA concentrations not only drove increased OVCAR-3 cell proliferation but also promoted glycolysis-based metabolism, as evidenced by elevated cell viability, accelerated cell proliferation, increased levels of ...
Purpose: Curcumin, a component of turmeric, has been shown to suppress inflammation and angiogenesis largely by inhibiting the transcription factor nuclear factor-κB (NF-κB). This study evaluates the effects of curcumin on ovarian cancer growth using an orthotopic murine model of ovarian cancer.. Experimental Design:In vitro and in vivo experiments of curcumin with and without docetaxel were done using human ovarian cancer cell lines SKOV3ip1, HeyA8, and HeyA8-MDR in athymic mice. NF-κB modulation was ascertained using electrophoretic mobility shift assay. Evaluation of angiogenic cytokines, cellular proliferation (proliferating cell nuclear antigen), angiogenesis (CD31), and apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) was done using immunohistochemical analyses.. Results: Curcumin inhibited inducible NF-κB activation and suppressed proliferation in vitro. In vivo dose-finding experiments revealed that 500 mg/kg orally was the optimal dose needed to ...
Ovarian Epithelial Cancer Treatment India, Ovarian Epithelial Cancer Treatment Cost In India Info On Cost Ovarian Epithelial Cancer Treatment Mumbai Delhi Bangalore India, Ovarian Epithelial Cancer Treatment Hospitals Center Mumbai India, Ovarian Epithelial Cancer Treatment Surgeon India
TY - JOUR. T1 - Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer. AU - Bogani, Giorgio. AU - Rossetti, Diego. AU - Ditto, Antonino. AU - Martinelli, Fabio. AU - Chiappa, Valentina. AU - Mosca, Lavinia. AU - Leone Roberti Maggiore, Umberto. AU - Ferla, Stefano. AU - Lorusso, Domenica. AU - Raspagliesi, Francesco. N1 - Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.. PY - 2018/9. Y1 - 2018/9. N2 - OBJECTIVE: Accumulating evidence support that complete cytoreduction (CC) at the time of secondary cytoreductive surgery (SCS) improves survival in patients affected by recurrent ovarian cancer (ROC). Here, we aimed to determine whether artificial intelligence (AI) might be useful in weighting the importance of clinical variables predicting CC and survival.METHODS: This is a retrospective study evaluating 194 patients having SCS for ROC. Using ...
TY - JOUR. T1 - Methiothepin suppresses human ovarian cancer cell growth by repressing mitochondrion-mediated metabolism and inhibiting angiogenesis in vivo. AU - Lee, Jin Young. AU - Yang, Changwon. AU - Lim, Whasun. AU - Song, Gwonhwa. N1 - Funding Information: This research was supported by the NRF of Korea grant funded by the Ministry of Science and ICT (2018R1C1B6009048). Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.. PY - 2020/7. Y1 - 2020/7. N2 - Ovarian cancer is the fifth leading cause of cancer-related deaths in women. Despite treatment, most patients experience relapse and the 5-year survival rate of ovarian cancer is less than 50%. Serotonin has cell growth-promoting functions in a variety of carcinomas, but the effect of serotonin receptor antagonists on ovarian cancer cells is unknown. In this study, it was confirmed that methiothepin, a serotonin receptor antagonist, suppresses the viability of, and induces apoptosis in, ovarian cancer cells. ...
Mucinous epithelial ovarian cancers are clinically and morphologically distinct through the various other histopathologic subtypes of ovarian cancer. signaling pathways. Immunohistochemistry of archived ovarian specimens showed significant overexpression of eight of the nine target antigens in mucinous ovarian tumor tissues, suggesting that plasma autoantibodies from mucinous ovarian cancer patients might have heightened reactivities with epitopes presented by these overexpressed antigens. Autoantibody profiling may have an unexpected power in uncovering key signaling pathways that are dysregulated in the system of interest. or mutations, have frequent mutations and modest ratio between the serum markers CA125 and carcinoembryonic antigen CEA (5). Molecular and pathologic studies also support a progression model for the development of mucinous ovarian tumors (6). Transitions between benign and malignant areas are seen in 80% of malignant mucinous adenocarcinomas. Identical mutations are ...
GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 Jan 11;:109539 Authors: El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G Abstract High-grade serous ovarian carcinoma (HGSOC) is the mos...
TY - JOUR. T1 - Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors. T2 - A novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. AU - Wang, Jun. AU - Lin, Lynne. AU - Parkash, Vinita. AU - Schwartz, Peter E.. AU - Lauchlan, Stuart C.. AU - Zheng, Wenxin. PY - 2003/1/20. Y1 - 2003/1/20. N2 - The role of FSHR expression in ovarian cancer development is not clear. We examined quantitative expression of FSHR in different types of OET, presumed precursor lesions and peritoneal implants and further discussed FSH as a key growth-promotion factor for the process of ovarian epithelial tumorigenesis. Thirty-five primary OET specimens, including 5 serous cystadenomas, 4 papillary serous cystadenomas, 9 SBTs and 17 serous carcinomas, were examined for quantitative FSHR expression. Ten paired samples (3 benign cystadenomas, 5 SBTs and 2 carcinomas) were obtained from several morphologically different areas, including ...
TY - JOUR. T1 - Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells. T2 - Cytoplasmic sequestration of CDK2 by p27. AU - Itamochi, Hiroaki. AU - Yoshida, Tomokazu. AU - Walker, Cheryl Lyn. AU - Bartholomeusz, Chandra. AU - Aoki, Daisuke. AU - Ishihara, Hideki. AU - Suzuki, Nao. AU - Kigawa, Junzo. AU - Terakawa, Naoki. AU - Ueno, Naoto T.. PY - 2011/9. Y1 - 2011/9. N2 - Objective: Ovarian clear cell carcinoma (CCC) carries a poor prognosis because of its insensitivity to chemotherapy. We previously found an association between reduced proliferation of CCC and chemoresistance; here we investigated the mechanism of the reduced proliferation. Methods: We assessed cell cycle function by measuring the activity of cyclin-dependent kinases (CDKs) and the protein expression of cyclins, the CDK inhibitors, and p53 in 22 ovarian cancer cell lines and 60 human ovarian cancer specimens. We examined the cellular location of p27, p27 phosphorylated at threonine 157 (p27Thr157), and ...
TY - JOUR. T1 - Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds. AU - Casey, Murray J.. AU - Bewtra, Chhanda. AU - Lynch, Henry T.. AU - Snyder, Carrie L.. AU - Stacey, Mark. PY - 2015/5/7. Y1 - 2015/5/7. N2 - Objective The aim of this study was to categorize and report endometrial cancers in mutation carriers from hereditary breast ovarian cancer families. Methods Our Hereditary Cancer Registry was searched for gynecologic and peritoneal cancers linked to mutations in BRCA1 or BRCA2. Invasive cancers were registered in 101 mutation carriers with complete pathology reports. Efforts were made to secure diagnostic surgical pathology tissues for review. All records and available diagnostic slides were meticulously studied, and primary cancers were classified. Findings Eight malignancies were classified as primary endometrial cancers. Five of these were low- or intermediate-grade endometrioid carcinomas, and 3 were pure serous carcinomas or contained ...
The expression of mismatch repair proteins hMSH2 and hMLH1 was investigated in human ovarian cancer cell lines and in biopsies of ovarian carcinomas obtained from 20 patients undergoing surgical operation. By Western blotting analysis hMSH2 protein was detected in all the tumor samples analyzed and in eight out of nine human ovarian cancer cell lines, while hMLH1 was undetectable in four out of 20 ovarian tumors and in five out of nine human ovarian cancer cell lines analyzed. The possible presence of frameshift mutations in the BAX gene, which contains a sequence of eight contiguous guanines in its third exon, was tested in all the samples. All the cell lines presented the normal alleles for the BAX gene while only in one of the tumor samples a heterozygous frameshift mutation was found. The frameshift mutation was associated to a low, almost undetectable, level of BAX protein which was instead present at much higher levels in all the other samples investigated. The results indicate that ...
Krukenbergs tumours are metastatic tumours of the ovary. The colon and stomach are the most common primary tumour sites. Breast, lung, and pancreas are the other sites of metastasis. These tumours constitute 5-10% of ovarian neoplasms.. The differential diagnosis from a primary ovarian tumour is very important for therapeutic approach. Krukenbergs tumours are bilateral in 60-80% of cases. Therefore whenever bilateral ovarian involvement is detected, a search for a primary site, especially in the gastrointestinal system, should be carried out. In contrast to primary ovarian tumours, the ovaries keep their shape in Krukenbergs tumour. Some other radiological findings give important clues. Early in the development of these tumours, the solid component is most prominent, as seen in this case. At US Krukenberg tumor typically present as bilateral, solid ovarian masses, with clear well defined margins. An irregular hyperechoic solid pattern and moth eaten like cyst formation are also ...
Ascites formation is often observed in ovarian cancer patients. Vascular permeability factor (VPF) may induce ascites formation. We established an animal model of ascites formation and re-accumulation by i.p. transplantation of a human ovarian adenocarcinoma cell line, NOS2, into nude mice. The form …
Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin released after 24 h from Compritol-Captex, Compritol-Miglyol, and Compritol NLCs being, respectively, equal to 33, 28, and 18% w/w on the total entrapped curcumin. Considering the slower curcumin release profile, Compritol NLCs were chosen to perform successive in vitro studies on ovarian cancer cell lines. The ...
Chemokine receptor-ligand interactions are important to support functioning of both normal and pathologic cells. The expression and function of chemokine receptors in epithelial ovarian carcinoma (EOC) is largely unknown. Here, we report that the lymphotactin receptor (XCR1) was expressed in primary and metastatic human epithelial ovarian carcinoma (EOC) specimens and cell lines. In contrast, expression of XCR1 was not detected in the normal ovary or in human normal ovarian surface epithelial cells. Our data indicate that XCL1 and XCL2 are either present in the malignant ascites or expressed by the ovarian carcinoma cells. The addition of lymphotactin (XCL1 and XCL2) stimulated migration and proliferation of XCR1-positive cells. Reduction of XCR1 expression in ovarian carcinoma cell line SKOV-3 resulted in abrogated diaphragm and peritoneal wall tumor formation and in reduced frequency of colonic, splenetic, and liver nodules in an in vivo xenograft mouse model. Taken together, our data suggest ...
Combination drug therapy appears a promising approach to overcome drug resistance and reduce drug-related toxicities in ovarian cancer treatments. In this in vitro study, we evaluated the antitumor efficacy of cisplatin in combination with Bithionol (BT) against a panel of ovarian cancer cell lines with special focus on cisplatin-sensitive and cisplatin-resistant cell lines. The primary objectives of this study are to determine the nature of the interactions between BT and cisplatin and to understand the mechanism(s) of action of BT-cisplatin combination. The cytotoxic effects of drugs either alone or in combination were evaluated using presto-blue assay. Cellular reactive oxygen species were measured by flow cytometry. Immunoblot analysis was carried out to investigate changes in levels of cleaved PARP, XIAP, bcl-2, bcl-xL, p21 and p27. Luminescent and colorimetric assays were used to test caspases 3/7 and ATX activity. The efficacy of the BT-cisplatin combination depends upon the cell type and
The expression of mRNA for the epidermal growth factor (EGF) receptor, EGF and transforming growth factor alpha (TGF-alpha) was determined in 76 malignant, six borderline and 15 benign primary ovarian tumours using the reverse transcriptase-polymerase chain reaction and related to clinical and pathological parameters. Of the malignant tumours, 70% (53/76) expressed EGF receptor mRNA, 31% (23/75) expressed EGF mRNA and 35% (26/75) expressed TGF-alpha mRNA. For the borderline tumours, four of six (67%) expressed EGF receptor mRNA, 1/6 (17%) expressed TGF-alpha mRNA and none expressed EGF mRNA. Finally, 33% (5/15) of the benign tumours expressed EGF receptor mRNA, whereas 40% (6/15) expressed EGF mRNA and 7% (1/15) expressed TGF-alpha mRNA. The presence of the EGF receptor in malignant tumours was associated with that of TGF-alpha (P = 0.0015) but not with EGF (P = 1.00), whereas there was no relationship between the presence of EGF and TGF-alpha (P = 1.00). EGF receptor mRNA expression was significantly
TY - JOUR. T1 - Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role. T2 - A Southwest Oncology Group ancillary study. AU - Hawes, Debra. AU - Liu, P. Y.. AU - Muggia, Franco M.. AU - Wilczynski, Sharon. AU - Cote, Richard J. AU - Felix, Juan. AU - Terada, Keith. AU - Belt, Robert J.. AU - Alberts, David S.. PY - 2002/12/1. Y1 - 2002/12/1. N2 - Objective. The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment. Methods. This study made use of samples from patients entered into a prospective randomized study of the Southwest Oncology Group (SWOG 8835) that treated patients with minimal residual disease at second-look ...
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer
TY - JOUR. T1 - Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. AU - Pearce, C. L.. AU - Near, A. M.. AU - Van Den Berg, D. J.. AU - Ramus, S. J.. AU - Gentry-Maharaj, A.. AU - Menon, U.. AU - Gayther, S. A.. AU - Anderson, A. R.. AU - Edlund, C. K.. AU - Wu, A. H.. AU - Chen, X.. AU - Beesley, J.. AU - Webb, P. M.. AU - Holt, S. K.. AU - Chen, C.. AU - Doherty, J. A.. AU - Rossing, M. A.. AU - Whittemore, A. S.. AU - McGuire, V.. AU - DiCioccio, R. A.. AU - Goodman, M. T.. AU - Lurie, G.. AU - Carney, M. E.. AU - Wilkens, L. R.. AU - Ness, R. B.. AU - Moysich, K. B.. AU - Edwards, R.. AU - Jennison, E.. AU - Kjaer, S. K.. AU - Hogdall, E.. AU - Hogdall, C. K.. AU - Goode, E. L.. AU - Sellers, T. A.. AU - Vierkant, R. A.. AU - Cunningham, J. C.. AU - Schildkraut, J. M.. AU - Berchuck, A.. AU - Moorman, P. G.. AU - Iversen, E. S.. AU - Cramer, D. W.. AU - Terry, K. L.. AU - Vitonis, A. F.. AU - Titus-Ernstoff, L.. AU - Song, ...
TY - JOUR. T1 - Ovarian cancer risk factors by tumor aggressiveness. T2 - An analysis from the Ovarian Cancer Cohort Consortium. AU - Fortner, Renee T.. AU - Poole, Elizabeth M.. AU - Wentzensen, Nicolas A.. AU - Trabert, Britton. AU - White, Emily. AU - Arslan, Alan A.. AU - Patel, Alpa. AU - Setiawan, V. Wendy. AU - Visvanathan, Kala. AU - Weiderpass, Elisabete. AU - Adami, Hans-Olov. AU - Black, Amanda. AU - Bernstein, Leslie. AU - Brinton, Louise A.. AU - Buring, Julie. AU - Clendenen, Tess. AU - Fournier, Agnes. AU - Fraser, Gary. AU - Gapstur, Susan M.. AU - Gaudet, Mia M.. AU - Giles, Graham G.. AU - Gram, Inger T.. AU - Hartge, Patricia. AU - Hoffman-Bolton, Judith. AU - Idahl, Annika. AU - Kaaks, Rudolf. AU - Kirsh, Victoria A.. AU - Knutsen, Synnove. AU - Koh, Woon-Puay. AU - Lacey, James V.. AU - Lee, I-Min. AU - Lundin, Eva. AU - Merritt, Melissa A.. AU - Milne, Roger L.. AU - Onland-Moret, N. Charlotte. AU - Peters, Ulrike. AU - Poynter, Jenny N.. AU - Rinaldi, Sabina. AU - Robien, ...
Epithelial ovarian cancer (EOC) is one of the leading causes of cancer deaths in women worldwide. Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function and plays an important role in sumoylation-mediated cellular pathways. Although sumoylation plays a key role in DNA repair and tumorgenesis, whether Ubc9 is involved in EOC progression remains unknown. In the present study, we constructed Ubc-9 expressed recombined plasmid pEGFP-N1-Ubc9. The mRNA levels of Ubc9 were confirmed in human ovarian cell lines before and after transfection with pEGFP-N1-Ubc9 or small interfering RNA (siRNA) targeted Ubc9 by real-time polymerase chain reaction (PCR). The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to observe the effect of Ubc9 on cell proliferation. The protein levels of Ubc9, and proliferation-related signals Akt and physphorylated Akt were determined by Western blot. Our results showed that proliferation of EOC
Doctors give trusted, helpful answers on causes, diagnosis, symptoms, treatment, and more: Dr. Hashemi on ovarian granulosa cell tumor: Sperm in men (&testosterone) and eggs/ova in women (& estrogens), and these are also the sites of germ cell tumors. Outside the gonads, the mediastinum and brain (pineal) are the most common extragonadal sites. These are known to produce markers (hcg, alphafeto-protein) and responsve and curable with chemotherapy. Hope this helps.
The therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in ovarian clear cell adenocarcinoma (CC) patients with measurable disease has yet to be elucidated. In this study, we used retrospective review to evaluate the results of treatment with a combination of PTX and PLT in CC patients with measurable disease. A total of 28 patients with measurable residual CC (15 cases with primary disease, 13 cases with recurrent disease) treated with combination PTX-PLT chemotherapy was identified through medical records from ten institutions. Clinical response to chemotherapy was evaluated using Response Evaluation Criteria in Solid Tumors criteria. Of the 28 cases, 8 of 15 patients with primary disease (53.3%) and 3 of 13 patients with recurrent disease (23.1%) responded to PTX-PLT chemotherapy. The response rate for cases with late recurrent disease (,12 months) was 20% (1/5), whereas the rate was 25% (2/8) for cases with early recurrent (,12 months) or refractory disease. Our ...
Oncolytics Biotech Inc. (Oncolytics) announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV) and intraperitoneal (IP)REOLYSIN®, Oncolytics proprietary formulation of the human reovirus. ... A cell with an activated Ras Pathway, which has lost its ability to…
Beamer, W G.; Shultz, K L.; Tennent, B J.; Azumi, N; and Sundberg, J P., Mouse model for malignant juvenile ovarian granulosa cell tumors. (1998). Faculty Research 1990 - 1999. 1160 ...
Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer (OC) patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that could better inform treatment remain unknown. Delivery of precision therapy requires improved integration of laboratory-based models and cutting-edge clinical research, with pre-clinical models predicting patient subsets that will benefit from a particular targeted therapeutic. Patient-derived xenografts (PDXs) are renewable tumor models engrafted in mice, generated from fresh human tumors without prior in vitro exposure. PDX models allow an invaluable assessment of tumor evolution and adaptive response to therapy. PDX models have been applied to pre-clinical drug testing and biomarker identification in a number of cancers including ovarian, pancreatic, breast, and prostate cancers. These models have been shown to
A new study finds that young women with early stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease.
Vascular endothelial growth factor (VEGF)-A inhibitors exhibit unseen high responses and toxicity in recurrent epithelial ovarian cancer suggesting an important role for the VEGF/VEGFR pathway. We studied the correlation of VEGF signalling and AKT/mTOR signalling. Using a tissue microarray of clinical samples (N=86), tumour cell immunohistochemical staining of AKT/mTOR downstream targets, pS6 and p4E-BP1, together with tumour cell staining of VEGF-A and pVEGFR2 were semi-quantified. A correlation was found between the marker for VEGFR2 activation (pVEGFR2) and a downstream target of AKT/mTOR signalling (pS6) (R=0.29; P=0.002). Additional gene expression analysis in an independent cDNA microarray dataset (N=24) showed a negative correlation (R=−0.73, P|0.0001) between the RPS6 and the VEGFR2 gene, which is consistent as the gene expression and phosphorylation of S6 is inversely regulated. An activated tumour cell VEGFR2/AKT/mTOR pathway was associated with increased incidence of ascites (χ2, P=0.002)
TY - JOUR. T1 - Ovarian clear cell adenocarcinoma revealed in a young patient during hormone therapy: a case report. AU - Kawai, Satoshi. AU - Ichikawa, Ryoko. AU - Ueda, Takahiro. AU - Urano, Makoto. AU - Kuroda, Makoto. AU - Fujii, Takuma. PY - 2016. Y1 - 2016. U2 - 10.20407/fmj.2.4_77. DO - 10.20407/fmj.2.4_77. M3 - Article. VL - 2. SP - 77. EP - 79. JO - Fujita medical journal. JF - Fujita medical journal. SN - 2189-7247. IS - 4. ER - ...
Learn how Avastin® (bevacizumab) works in recurrent platinum-treated ovarian cancer including platinum-resistant ovarian cancer (prOC) and platinum-sensitive ovarian cancer (psOC) Metastatic Colorectal Cancer (mCRC) Avastin is approved to treat metastatic colorectal cancer (mCRC) for: First- or second-line treatment in combination with intravenous 5-fluorouracil-based chemotherapy Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes Avastin. Avastin is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body. Glioblastoma (GBM) Avastin is approved to treat glioblastoma (GBM) when taken alone in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM). The effectiveness of Avastin in rGBM is based on tumor response. Currently, no data have shown whether or not Avastin improves disease
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This roadmap for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
Semaphorins comprise a family of molecules that influence neuronal growth and guidance. Class-3 semaphorins, semaphorin-3B (SEMA3B) and semaphorin-3F (SEMA3F), illustrate their effects by forming a complex with neuropilins (NP-1 or NP-2) and plexins. We examined the status and regulation of semaphorins and their receptors in human ovarian cancer cells. A significantly reduced expression of SEMA3B (83 kDa), SEMA3F (90 kDa), and plexin-A3 was observed in ovarian cancer cell lines when compared with normal human ovarian surface epithelial cells. The expression of NP-1, NP-2, and plexin-A1 was not altered in human ovarian surface epithelial and ovarian cancer cells. The decreased expression of SEMA3B, SEMA3F, and plexin-A3 was confirmed in stage 3 ovarian tumors. The treatment of ovarian cancer cells with luteinizing hormone, follicle-stimulating hormone, and estrogen induced a significant upregulation of SEMA3B, whereas SEMA3F was upregulated only by estrogen. Cotreatment of cell lines with a ...
Mutations of NH2-terminal β-catenin sequences have been demonstrated in various human tumor types, including colorectal carcinomas (24 , 39) , melanomas (40) , hepatoblastomas (41) , medulloblastomas (42) , prostatic carcinomas (43 , 44) , and uterine endometrial carcinomas (45, 46, 47, 48) , particularly endometrioid adenocarcinomas with squamous differentiation (10) . Prior studies of ovarian carcinomas have indicated that β-catenin mutations are common only in OEAs, with estimated mutation frequencies of 16-54% (10, 11, 12, 13, 14) .. We have pursued our studies of the prevalence and mechanisms underlying β-catenin deregulation in 45 histologically verified frozen primary OEA tissues. This is, in fact, a substantial number of primary tumors of this particular histological subtype, because only 10-20% of ovarian carcinomas are endometrioid (49) . We identified CTNNB1 exon 3 mutations in 31% of our primary ovarian endometrioid carcinomas. Mutations inactivating the APC, AXIN1, and AXIN2 ...
Many studies have compared open surgery and laparoscopic surgery in gynecology. Furthermore, several studies have compared conventional laparoscopy using multiple ports and laparotomy in ovarian cancer [9,18,19-21]. However, no previous study has compared single-port laparoscopic surgery and laparotomy in ovarian cancer, although several studies have compared single-port and multiport laparoscopic surgery for benign gynecologic diseases [13,22]. Therefore, this study is the first to investigate the feasibility of single-port laparoscopic surgery by comparing SPLS and staging laparotomy in early ovarian cancer.. According to our results, SPLS has several advantages in terms of surgical outcomes, such as lower estimated blood loss, lower transfusion rate, less postoperative pain, and shorter postoperative hospital stay, while showing no significant differences in survival outcomes. Less blood loss is well known as one of the main advantages of minimally invasive surgery. In this study, there was ...
TY - JOUR. T1 - The chemosensitivity of nodal metastases in recurrent epithelial ovarian cancer. AU - Kataoka, F.. AU - Tsuda, H.. AU - Nomura, H.. AU - Chiyoda, T.. AU - Tominaga, E.. AU - Suzuki, A.. AU - Susumu, N.. AU - Aoki, D.. PY - 2011/5/11. Y1 - 2011/5/11. N2 - Purpose: In this study, we compared second-line chemotherapy effects of nodal metastases with other metastases sites. Methods: The medical records of 44 women with recurrent ovarian cancer who received second-line chemotherapy were retrospectively reviewed. Results: Median age at the time of second-line chemotherapy was 55 years (range: 31-74). Recurrent sites were as follows: 29 patients had a solitary site (abdominal cavity: 8; lymph node: 3; pelvic cavity: 10; liver: 4; lung: 4) and 15 patients had multiple sites In total, the response rate was 30% (CR: 8, PR: 5). The response rate in sensitive cases was higher than in refractory/resistant cases (50% vs 5% p = 0.002). However, age, chemotherapy regimen, histologic type and ...
Inclusion Criteria:. - Have recurrent epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer. - Have platinum-resistant (recurrence within 6 months of a platinum-containing regimen) or platinum refractory (progression while on platinum) disease - Have measurable disease according to RECIST or detectable disease. o Measurable disease is defined as the presence of at least one uni-dimensionally measurable lesion greater than or equal to 20 mm by conventional techniques, including palpation, plain x-ray, CT scan or MRI, or greater than or equal to 10 mm by spiral CT scan. o Detectable disease is defined in a patient as one who does not have measurable disease but has at least one of the following conditions: 1) Baseline values of cancer antigen 125 (CA-125) at least twice the upper limit of normal; 2) Ascites and/or pleural effusion attributed to tumor; 3) solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST definitions for target lesions. ...
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with th …
Ovarian cancer is the leading cause of death from gynecologic cancer in women worldwide. According to the National Cancer Institute, ovarian cancer has the highest mortality rate among all the reproductive cancers in women. Advanced stage diagnosis and chemo/radio-resistance is a major obstacle in treating advanced ovarian cancer. The most commonly employed chemotherapeutic drug for ovarian cancer treatment is cis-platin. As with most chemotherapeutic drugs, many patients eventually become resistant to cis-platin and therefore, diminishing its effect. The efficacy of current treatments may be improved by increasing the sensitivity of cancer cells to chemo/radiation therapies. The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of
Objectives: Adherence to National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer treatment improves patient outcomes. The aim of this study was to assess disparities associated with ovarian cancer treatment in the state of Kentucky and central Appalachia. Methods: Data on patients diagnosed as having ovarian cancer from 2007 through 2011 were extracted from administrative...
The addition of bevacizumab (Avastin) to gemcitabine and carboplatin, followed by bevacizumab until disease progression, resulted in significantly improved progression-free survival compared to gemcitabine and carboplatin plus placebo among women with platinum-sensitive recurrent ovarian, primary periotoneal, or fallopian tube cancer. Results from the phase III OCEANS (Ovarian Cancer Study Comparing the Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease) trial were published in the Journal of Clinical Oncology.1 The study was sponsored by Genentech, which manufactures bevacizumab.. Analysis of Progression-free Survival. Both treatment groups consisted of 242 patients with histologically confirmed disease progression and ≥ 6 months after completion of front-line platinum-based chemotherapy. At the time of the final [progression-free survival] analysis (338 events), the median follow-up was 24 months, the authors reported. The median ...
Ovarian cancer affects the female ovaries, the part of the reproductive system that produces eggs. The cancer cells, in this case, originate in the lining of the ovaries. There are no special ovarian cancer signs and symptoms, but it may produce specific symptoms only when it travels to other nearly tissues and organs, including the pelvis and the stomach.. Last stage ovarian cancer is extremely difficult to treat. Ovarian cancer treatment options include chemotherapy and surgery. For the cancer cases that has spread extensively, a surgery is performed. During ovarian cancer surgery, both the ovaries are removed along with the Fallopian tubes and the uterus. In addition, some abdominal tissues and the nearby lymph nodes may also be removed.. Recovery after ovarian cancer surgery takes a few weeks. The patients is typically required to stay in the hospital for at least a week after the surgery.. ...
Dishevelled family proteins (DVL1, DVL2 and DVL3) are cytoplasmic mediators involved in canonical and non-canonical Wnt signaling that are important for embryonic development. Since Wnt signaling promotes cell proliferation and invasion, its increased activation is associated with cancer development as well. To get deeper insight into the behavior of Dishevelled proteins in cancer, we studied their expression in serous ovarian carcinomas [both low- (LGSC) and high-grade (HGSC)], and HGSC cell lines OVCAR5, OVCAR8 and OVSAHO. DVL protein expression in serous ovarian carcinomas tissues was analyzed using immunohistochemistry while DVL protein and mRNA expressions in HGSC cell lines were analyzed using western blot and quantitative real-time PCR. DVL1 protein expression was significantly higher in LGSC compared with normal ovarian tissue, while DVL3 was overexpressed in both LGSC and HGSC. DVL2 and DVL3 protein expression was higher in HGSC cell lines when compared with normal control cell line ...
A look at the following clinical trial: Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function.
The manganese superoxide dismutase (MnSOD), located in the mitochondria, is a major antioxidant enzyme that plays an important role in protecting cells from oxidative damage. MnSOD has been suggested to have tumor suppressor function in many cancer types. Surprisingly, the levels of MnSOD in ovarian carcinomas were found elevated compared with normal ovarian epithelium. In this study, we aimed to investigate the levels of MnSOD protein in ovarian cancer cell lines and ovarian surface epithelial (OSE) cells and a possible link between MnSOD expression and resistance to apoptosis. We showed that MnSOD protein was abundant in most ovarian cancer cell lines but was at very low levels in OSE. MnSOD overexpression in ovarian cancer cells caused a ~50% decrease of cell proliferation and an increase of apoptosis, whereas targeted inhibition of endogenous MnSOD using small interfering RNA promoted growth of these cells, confirming the effect was MnSOD specific. Furthermore, stimulation of mitochondrial ...
The effective treatment of ovarian serous carcinoma remains a major challenge because of the recurrence of platinum-resistant tumors. The mechanism of platinum-resistance may involve decreased cellular uptake caused by abnormalities of transporters, intracellular cisplatin inactivation (e.g., caused by glutathione), and increased DNA repair (18). However, no available therapy prevents platinum-resistance.. TBX2 is overexpressed by numerous human cancers (7-14). TBX2 may serve as a prognostic factor of breast cancer (7,9), melanoma (8), gastric cancer (10), prostate cancer (11), laryngeal squamous cell carcinoma (12), and non-small cell lung cancer (14). TBX2 is associated with resistance to therapeutic drugs such as cisplatin and doxorubicin (15,16), and TBX2 therefore may serve as a therapeutic target.. One report shows that chromosome 17q12-q24 harbors strong candidates for ovarian tumorigenesis, such as LASP1 (17q12), TGF11 (17q21.32), MUL (17q23.2), TBX2 (17q23.2), AXIN2 (17q24.3), and GRB2 ...
TY - JOUR. T1 - The mTORC2 Component Rictor Contributes to Cisplatin Resistance in Human Ovarian Cancer Cells. AU - Im-aram, Akechai. AU - Farrand, Lee. AU - Bae, Seung Min. AU - Song, Gwonhwa. AU - Song, Yong Sang. AU - Han, Jae Yong. AU - Tsang, Benjamin K.. PY - 2013/9/23. Y1 - 2013/9/23. N2 - Resistance to cisplatin-based therapy is a major cause of treatment failure in human ovarian cancer. A better understanding of the mechanisms of cisplatin resistance will offer new insights for novel therapeutic strategies for this deadly disease. Akt and p53 are determinants of cisplatin sensitivity. Rictor is a component of mTOR protein kinase complex 2, which is required for Akt phosphorylation (Ser473) and full activation. However, the precise role of rictor and the relationship between rictor and p53 in cisplatin resistance remains poorly understood. Here, using sensitive wild-type p53 (OV2008 and A2780s), resistant wild-type p53 (C13* and OVCAR433), and p53 compromised (A2780cp, OCC1, and SKOV-3) ...
Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid platinum inefficacy and to exploit platinum sensitivity. TOV-21G devoid of FANCF expression, OV-90 and SKOV-3 were employed as examples of platinum-sensitive, platinum-intermediate and platinum-resistant cell lines, respectively. Antineoplastic agents examined included mitomycin C, doxorubicin, etoposide, gemcitabine, chlorambucil, paclitaxel, triapine and X-rays. Their effectiveness against cell lines was analyzed by clonogenic assays. Cytotoxic profiles of mitomycin C and carboplatin were similar, with mitomycin C exhibiting greater potency and selectivity against TOV-21G than carboplatin. Cytotoxic profiles of doxorubicin, etoposide and X-rays overlapped with that of ...
TY - JOUR. T1 - Differences in thermostability of thymidine kinase isoenzymes in normal ovary and ovarian carcinoma. AU - Demeter, A.. AU - Abonyi, M.. AU - Look, K. Y.. AU - Keszler, G.. AU - Staub, M.. AU - Weber, G.. PY - 2001/4/17. Y1 - 2001/4/17. N2 - Thymidine kinase I (TK 1 EC. the most specific and cell-cycle regulated salvage enzyme for pyrimidine nucleoside supply of DNA synthesis is a promising target to rationally designed chemo- and other therapies. The present study was undertaken to compare the heat stability of TK isoenzymes of both normal ovarian and epithelial ovarian cancer cells. Tissue extracts of epithelial ovarian carcinomas (N = 7) and normal ovaries (N=9) were analyzed for thymidine kinase activity using the polyethyleneimine-cellulose disc radioassay. The TK activity in extracts of ovarian carcinomas was 12-fold higher than in extracts of normal ovaries. The TK activity of ovarian carcinomas decreased significantly even after 30 minutes incubation at 37°C ...
Fibroids can be mistaken for ovarian neoplasms. An uncommon tumor which may be mistaken for a fibroid is Sarcoma botryoides. It ... "Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications". Human Reproduction Update (Review). 21 (1): 1-12 ... at certain doses they would completely inhibit estrogen production in the fibroid while not largely affecting ovarian ... and contribute significantly to ovarian steroid-dependent growth of fibroids. These stem-progenitor cells are deficient in ...
... a rare ovarian neoplasm. Case report and review of literature". Gynecol. Endocrinol. 24 (4): 230-4. doi:10.1080/ ... Animal studies a suggest possible link with C8 (C8HF15O2, Perfluorooctanoic acid). Presence of an ovarian tumour plus hormonal ... is a member of the sex cord-stromal tumour group of ovarian and testicular cancers. It arises from Leydig cells. While the ...
... in ovarian neoplasms predicts shorter survival". Hum. Pathol. 28 (6): 686-92. doi:10.1016/S0046-8177(97)90177-5. PMID 9191002. ...
Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989; 74:921. Magrina JF, Espada M, Munoz R, ... In premenopausal women, adnexal masses include ovarian cysts, ectopic (tubal) pregnancies, benign (noncancerous) or malignant ( ... cancerous) tumors, endometriomas, polycystic ovaries, and tubo-ovarian abscess. The most common causes for adnexal masses in ...
"Old abdominal pregnancy presenting as an ovarian neoplasm". Journal of Korean Medical Science. 17 (2): 274-75. doi:10.3346/jkms ... Lithopedia can originate both as tubal and ovarian pregnancies, although tubal pregnancy cases are more common. * After death ... following the rupture of the placental and ovarian membranes; and Lithokelyphopedion ("Stone Sheath [and] Child"), where both ...
A rare ovarian neoplasm. Case report and review of literature". Gynecological Endocrinology. 24 (4): 230-4. doi:10.1080/ ... is a testosterone-secreting ovarian tumor and is a member of the sex cord-stromal tumour group of ovarian and testicular ... Presence of an ovarian tumour plus hormonal disturbances suggests a Sertoli-Leydig cell tumour. However, hormonal disturbance ... "DICER1 Mutations in Familial Multinodular Goiter With and Without Ovarian Sertoli-Leydig Cell Tumors". JAMA. 305 (1): 68-77. ...
These epigenetic defects occurred in various cancers (e.g. breast, ovarian, colorectal and head and neck). Two or three ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ...
It appears in the sex cord-stromal tumour group of ovarian neoplasms. Ovary fibromas are most frequent during middle age, and ... There may be thecomatous areas (fibrothecoma). The presence of an ovarian fibroma can cause ovarian torsion in some cases. ...
... s or theca cell tumors are benign ovarian neoplasms composed only of theca cells. Histogenetically they are classified ... October 2004). "Ovarian thecoma associated in the first trimester of pregnancy". J. Obstet. Gynaecol. Res. 30 (5): 368-71. doi: ... Grossly and microscopically, it consists of the ovarian cortex. Microscopically, the tumour cells have abundant lipid-filled ...
Saba, Luca; Acharya, U. Rajendra; Guerriero, Stefano; Suri, Jasjit S. (2014). Ovarian Neoplasm Imaging. Springer Science & ... Ovarian teratomas represent about a quarter of ovarian tumors and are typically noticed during middle age. Testicular teratomas ... Treatment of coccyx, testicular, and ovarian teratomas is generally by surgery. Testicular and immature ovarian teratomas are ... Ovarian teratomas often present with abdominal or pelvic pain, caused by torsion of the ovary or irritation of its ligaments. A ...
Ovarian serous cystadenoma Pancreatic mucinous cystadenoma Solid pseudopapillary neoplasm Jais, B; Rebours, V; Malleo, G; ... such as the intraductal papillary mucinous neoplasm and the mucinous cystic neoplasm), serous cystic neoplasms are almost ... mixed serous-endocrine neoplasm, and VHL-associated serous cystic neoplasm. This latter classification scheme is useful because ... Serous cystic neoplasms that have spread ("metastasized") to another organ are considered malignant and are designated "serous ...
2009). "Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms". ...
Brenner tumors are an uncommon subtype of the surface epithelial-stromal tumor group of ovarian neoplasms. The majority are ... Histologically, Leydig cell tumors of the testes and ovarian stromal Leydig cell tumors (ovarian hyperandrogenism and ... the ovarian granulosa cell tumor, with the fluid-filled spaces Call-Exner bodies between the granulosa cells. Transitional cell ... producing ovarian tumor that was diagnosed by selective venous hormone sampling". Reproductive Medicine and Biology. 17 (4): ...
... s are a class of ovarian neoplasms that may be benign or malignant. Neoplasms in this group are ... One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian ... For more general information, see ovarian cancer. Research suggests that in the first line treatment of Endometrial Ovarian ... of all ovarian neoplasms In some cases mucinous tumors are characterized by more cysts of variable size and a rarity of surface ...
Sertoli-Leydig cell tumour is part of the sex cord-stromal tumour group of ovarian neoplasms. These tumors produce both sertoli ...
Laparoscopy may be an option if the surgeon is particularly skilled in removing ovarian neoplasms via laparoscopy intact. If ... A gonadoblastoma is a complex neoplasm composed of a mixture of gonadal elements, such as large primordial germ cells, immature ...
"A case of ovarian metastasis of gallbladder carcinoma simulating primary ovarian neoplasm: diagnostic pitfalls and review of ... ovarian stroma and testis. The NCI Thesaurus identifies the following types of signet ring cell Castration cell, a non- ...
Immunohistochemistry may help in diagnosing Krukenberg tumors from primary ovarian neoplasms but needs to be applied with ... In most countries, cancer that has metastasized to the ovary accounts for only about 1 to 2% of ovarian cancer; in the ... Krukenberg tumors can occasionally provoke a reaction of the ovarian stroma which leads to hormone production, that results in ... "Virilizing ovarian Krukenberg tumor in a 27-year-old pregnant woman. A case report and literature review". European Journal of ...
They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign ... Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more ... "Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles". Modern Pathology. 27 (1): 128 ... CTNNB1 mutations are significantly different in low-grade ovarian endometrioid carcinomas (53%) compared with low-grade ...
Of solid tumor neoplasms, ovarian cancer is most likely to provoke eosinophilia, though any other cancer can cause the ... The World Health Organization classifies these disorders into a) Myeloid and lymphoid neoplasms with eosinophilia and ... Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ...
Ovarian neoplasms Germ cell tumor Seen most often in young women or adolescent girls. Other germ cell tumors are: Endodermal ... The ovarian pedicle is made up part of the fallopian tube, mesovarium, ovarian ligament, and ovarian blood vessels.[5] ... Cryopreservation of ovarian tissue, often called ovarian tissue cryopreservation, is of interest to women who want to preserve ... If the egg fails to release from the follicle in the ovary an ovarian cyst may form. Small ovarian cysts are common in healthy ...
... trophoblastic neoplasms, and ovarian carcinoma. Moreover, it also has been used as an immunosuppressive drug for various ...
This includes Wilms tumor, rhabdomyosarcoma, Ewing's sarcoma, trophoblastic neoplasm, testicular cancer, and certain types of ... ovarian cancer. It is given by injection into a vein. Most people develop side effects. Common side effects include bone marrow ...
... ovarian neoplasms (malignant or benign), and peritoneal effusions. Atypical mesothelial hyperplasia. ... Peritoneal mesothelial hyperplasia can be encountered in inflammatory pelvic disease with tubo-ovarian abscess, ...
Saba, Luca; Acharya, U. Rajendra; Guerriero, Stefano; Suri, Jasjit S. (2014). Ovarian Neoplasm Imaging (in ଇଂରାଜୀ). Springer ... ovarian torsion),ଟେଷ୍ଟିକୁଲାର ଟର୍ସନ ବା ହାଇଡ୍ରପ୍ସ ଫିଟାଲିସ (hydrops fetalis) ରୋଗ ହୁଏ ।[୧][୨][୭] ... ovarian tumors) ମଧ୍ୟରୁ ଏକ ଚତୁର୍ଥାଂଶ ଟେରାଟୋମା ଥାଏ ଓ ଏହା ମଧ୍ୟ ବୟସରେ ନ‌ଜରକୁ ଆସେ । [୧୦] ସମସ୍ତ ଟେସ୍ଟିକୁଲାର କର୍କଟ (testicular cancers ...
The ovarian fibroma, also fibroma, is a benign sex cord-stromal tumour. Ovarian fibromas represent 4% of all ovarian neoplasms ... There may be thecomatous areas (fibrothecoma). The presence of an ovarian fibroma can cause ovarian torsion in some cases. ... Vaidya, SA; Kc, S; Sharma, P; Vaidya, S (2014). "Spectrum of ovarian tumors in a referral hospital in Nepal". Journal of ... Diagnosis is usually made by ultrasonography showing a solid ovarian lesion, or, on some occasions, mixed tumors with solid and ...
... s, or ovarian neoplasms, are tumors arising from the ovary. They can be benign or malignant (ovarian cancer). They ... Ovarian tumors are classified according to the histology of the tumor, obtained in a pathology report. Histology dictates many ... Vaidya, SA; Kc, S; Sharma, P; Vaidya, S (2014). "Spectrum of ovarian tumors in a referral hospital in Nepal". Journal of ... Unless otherwise specified in boxes, reference is: Vaidya, SA; Kc, S; Sharma, P; Vaidya, S (2014). "Spectrum of ovarian tumors ...
Mucinous tumors are part of the surface epithelial-stromal tumor group of ovarian neoplasms, and account for approximately 36% ... Ovarian Cancer. In: Pharmacotherapy: A pathophysiologic approach.8th ed. Dipiro JT, Talbert RL, Yee GC et al., New York: McGraw ... It is well documented that malignancy may be only focally present in mucinous neoplasms of the ovary, so thorough sampling is ... Pseudomyxoma peritonei may present as a result of an ovarian mucinous tumor, however this is a rare cause of this condition, ...
... is the most common ovarian neoplasm, representing 20% of ovarian neoplasms, and is benign. It has a very superficial ... resembling ovarian surface epithelium Ovarian serous cystadenoma accounts for the largest proportion of benign ovarian tumours ... Serous ovarian cystadenocarcinomas account for ~25% of serous tumours. Ovarian cancer Pancreatic serous cystadenoma Serous ... Serous cystadenomas (of the ovary) are not related to serous cystadenomas of the pancreas, i.e. the presence of an ovarian or ...
They can develop further into a variety of other neoplasms, including choriocarcinoma, yolk sac tumor, and teratoma. They occur ... The Risk of Ovarian Malignancy algorithm uses CA-125 levels and HE4 levels to calculate the risk of ovarian cancer; it may be ... Ovarian cancer is related to the amount of time spent ovulating. Thus not having children is a risk factor for ovarian cancer, ... Ovarian carcinoma is the most common type of ovarian cancer, comprising more than 95% of cases. There are five main subtypes of ...
Expression of PAX8 is increased in neoplastic renal tissues, Wilms tumors, ovarian cancer and Müllerian carcinomas. For this ... aka Hurthle-Cell Neoplasms).[15] Tumors expressing the PAX8/PPARy are usually present in at a young age, small in size, present ... ovarian cancer cells, bladder, prostate, and endometrial carcinomas.[9] The mechanism of switching on the genes is unknown. ...
Several severe adverse health effects, such as an increased incidence of cancers, thyroid diseases, CNS neoplasms, and possibly ... ovarian, lung, colon, and thyroid tissues as the most radiosensitive among women. For example, the FGR 13 has estimated that ... a female fetus may therefore be multigenerational and increase both the daughter's and grandchildren's risks for ovarian cancer ...
Salivary gland neoplasm. *Sarcoma. *Skin cancer. *Small intestine cancer. *Small-cell carcinoma ...
Mutations in BRCA1 and BRCA2, important risk factors for ovarian cancer and breast cancer in women, have also been implicated ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ...
Chronically insufficient intake of folic acid may increase the risk of colorectal, breast, ovarian, pancreas, brain, lung, ... Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ...
cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm. *Mucinous cystic neoplasm ... Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous cystadenocarcinoma. ...
Arm-Wide Patterns of Tumor-Exclusive Platform-Consistent Alterations Encoding for Cell Transformation and Predicting Ovarian ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ...
"Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.". European journal of cancer ( ... canser thorasig, clefyd y fron, breast neoplasm Arbenigedd meddygol. Oncoleg Ffeiliau perthnasol ar Gomin Wicimedia. ... The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users].". Medicinski pregled 63 (9-10): 657- ... Mewn llai 5% o achosion, mae geneteg yn chwarae rhan fwy allweddol wrth greu hereditary breast-ovarian cancer syndrom. Mae hyn ...
Colorectal, lung, ovarian and brain cancer. 3. $6.56 billion. Trastuzumab. Herceptin. Roche. Breast, esophagus and stomach ... Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... Female infertility by chemotherapy appears to be secondary to premature ovarian failure by loss of primordial follicles.[91] ... Roness H, Kalich-Philosoph L, Meirow D (2014). "Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal ...
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
It is the most common malignant ovarian tumor.[citation needed] Contains complex multi-loculated cyst but with exuberant solid ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ...
8560-8580) Complex epithelial neoplasms. Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that ... The two biggest risk factors for ovarian carcinoma are age and family history.[26] ... and imaging studies in a logical fashion to obtain information about the size of the neoplasm and the extent of its invasion ... "Ovarian Carcinoma Associated with endometriosis". European Journal of Obstetrics and Gynecology and Reproductive Biology. 170 ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... "Screening for Ovarian Cancer". U.S. Preventive Services Task Force. 2004. Archived from the original on 23 October 2010.. ... Routine screening is not recommended for bladder cancer,[136] testicular cancer,[137] ovarian cancer,[138] pancreatic cancer,[ ... ovarian cancer and certain lung cancers.[146] Chemotherapy is curative for some cancers, such as some leukemias,[147][148] ...
Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.[4] As an immune suppressor it is used in ... Myeloproliferative neoplasms, including acute leukemia, non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 ...
Mutations in this gene are correlated with gastric, breast, colorectal, thyroid, and ovarian cancers. Loss of function is ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ...
"Prevalence of Mycoplasma Conserved DNA in Malignant Ovarian Cancer Detected Using Sensitive PCR-ELISA"। Gynecologic Oncology। ...
Trophoblastic neoplasms derive from trophoblastic tissue. Examples include: *Choriocarcinoma. *Hydatidiform mole. Mechanism[ ...
Glandular and epithelial neoplasms (ICD-O 8010-8589). Epithelium. Papilloma/carcinoma. (8010-8139). *Small cell carcinoma ... Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous cystadenocarcinoma ...
However, ovarian disease has not been observed in every trial of zona pellucida vaccination, and when observed, has not always ... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... The main function of hCG is to sustain the ovarian corpus luteum during pregnancy past the time it would normally decay as part ... One concern with zona pellucida vaccination, in particular, is that in certain cases it appears to be correlated with ovarian ...
... deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ... ovarian, pancreas, brain, lung, cervical, and prostate cancers.[7][39][40][41][42] Other studies showed that excessive dietary ...
Of solid tumor neoplasms, ovarian cancer is most likely to provoke eosinophilia, though any other cancer can cause the ... Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ...
Ovarian cancer. *Ovarian epithelial cancer (surface epithelial-stromal tumor). *Ovarian germ cell tumor ... Multiple myeloma/plasma cell neoplasm. *Myelodysplastic syndromes. *Mucosa-associated lymphoid tissue lymphoma ...
These were cancers of the brain, lung, bowel, breast, and bladder, and other neoplasms. Not only are benzodiazepines associated ... "Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two ... use for more than one to six months at prescribed doses is associated with an increased risk of the development of ovarian ...
Wathes DC, Swann RW (1982). "Is oxytocin an ovarian hormone?". Nature. 297 (5863): 225-7. doi:10.1038/297225a0. PMID 7078636.. ... Luck MR, Jungclas B (1987). "Catecholamines and ascorbic acid as stimulators of bovine ovarian oxytocin secretion". J. ...
... which may be benign neoplasms) or else a malignant neoplasm (cancer). These neoplasms are also indicated, in the diagram below ... "Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma" ... The Hallmarks of Cancer as evolutionary adaptations in a neoplasm[edit]. In their landmark paper, The Hallmarks of Cancer,[3] ... Cells in neoplasms compete for resources, such as oxygen and glucose, as well as space. Thus, a cell that acquires a mutation ...
Neoplasms of the Vulva and Vagina. in Holland-Frei Cancer Medicine - 6th Ed. Kufe, DW et al. editors. BC Decker Inc., Hamilton ... Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
Other types of cancer for which RIT has therapeutic potential include prostate cancer,[8] metastatic melanoma,[9] ovarian ... By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ...
Erratum for "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms"". Science. 259 ( ... Premature ovarian failure 7. *SOX10 *Waardenburg syndrome 4c. *Yemenite deaf-blind hypopigmentation syndrome ... 1990). "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms". Science. 250 (4985): ... Li F.P.; Fraumeni J.F. (October 1969). "Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?". Ann. ...
The ovarian disease has two forms, juvenile and adult, both characterized by indolent growth,[1] and therefore has high ... They are esterogen secreting tumors and present as large, complex, ovarian masses. These tumours are part of the sex cord- ... Walker ML, Anderson DC, Herndon JG, Walker LC (2009). "Ovarian aging in squirrel monkeys (Saimiri sciureus)". Reproduction. 138 ... see Ovarian cancer and Testicular cancer). These tumours should be considered malignant and treated in the same way as other ...
Contrast-Enhanced Transvaginal Sonography of Ovarian Masses: Potential Role in Early Diagnosis of Ovarian Cancer ... CT and MR of Benign Ovarian Germ Cell Tumours Ingrid Millet, H. Perrochia, E. Pages-Bouic, F. Curros-Doyon, G. Rathat, P. ... Ovarian Tumor Characterization Using 3D Ultrasound U. Rajendra Acharya, M. Muthu Rama Krishnan, Luca Saba, Filippo Molinari, ... Epidemiology of Epithelial Ovarian Carcinoma Anna Maria Paoletti, Bruno Piras, Monica Pilloni, Maria Francesca Marotto, Marisa ...
Understanding the Value of Tumor Markers in Pediatric Ovarian Neoplasms.. Lawrence AE1, Fallat ME2, Hewitt G3, Hertweck P4, ... A retrospective review of girls 2-21 years who presented for surgical management of an ovarian neoplasm across 10 childrens ... Tumor marker testing is helpful in preoperative risk stratification of ovarian neoplasms for malignancy. Given the variety of ... Prospective studies may help further elucidate the predictive value of tumor markers in a pediatric ovarian neoplasm population ...
The most common treatment for an ovarian neoplasm varies depending on the severity of the neoplasm, but generally speaking, it ... Some neoplasms have the potential to become malignant. A benign ovarian neoplasm does not present a risk of spreading elsewhere ... An ovarian neoplasm is an abnormal growth located on or in the ovaries. Some neoplasms are or have the potential to become ... Benign ovarian neoplasms are generally left untreated and may dissolve over time. Neoplasms are abnormal groups of cells caused ...
Ovarian Neoplasms. Neoplasms. Endocrine Gland Neoplasms. Neoplasms by Site. Ovarian Diseases. Adnexal Diseases. Genital ... MedlinePlus related topics: Ovarian Cancer Genetic and Rare Diseases Information Center resources: Ovarian Cancer Ovarian ... Diaphragmatic Resection And Gynecological Ovarian Neoplasm (DRAGON). The safety and scientific validity of this study is the ... Ovarian cancer represents the leading cause of death from gynecologic malignancies. The majority of patients present with ...
Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.. Chen CA1, Cheng ... The median VEGF serum level in ovarian cancer patients was 458.7 pg/mL. The 75% quatile was defined as the cutoff level. ... Pretreatment VEGF serum levels might be regarded as an additional factor in predicting the outcome of ovarian cancer patients. ... Anti-angiogenic therapy, if is available, might be a new treatment modality for ovarian cancer patients with poor prognosis ...
Mesenchymal Ovarian Neoplasms with stained slides of pathology. ... Mesenchymal Ovarian Neoplasms. High Quality Pathology Images of ... High Quality Pathology Images of Benign and Malignant Neoplasms and Related Entities. ... Mesenchymal Ovarian Neoplasms. Home Gynecologic Ovary Misc. Mesenchymal Ovarian Neoplasms Leiomyoma of Ovary. Ovary : Leiomyoma ...
possible changes in V1R expression in the ovarian neoplasms are specific to that receptor. subtype. Ovarian artery samples will ... ovarian neoplasm histology.. Preliminary results:. Recently, our labs have isolated and analyzed human mesenteric arteries for ... Evaluation of Vasopressin and Vasopressin Receptor Expression in the Arteries and Veins of Ovarian Neoplasms. Trial Phase:. N/A ... by measuring the AVP protein directly in the ovarian neoplasm blood vessels collected.. 6. PLAN: Women, 18 years old or greater ...
Browse by Outcome: Ovarian Neoplasms (1 article). % of records by year: 1965 2017 ...
Also known as: Ovarian neoplasm / Ovarian Neoplasms / Neoplasms,Ovarian / Ovarian neoplasia / Ovarian tumor / Ovarian neoplasm ... Neoplasms, Ovarian Suspended Phase 1 Trials for Veliparib (DB07232). Back to Neoplasms, Ovarian ...
Ovarian Neoplasms. Neoplasms. Endocrine Gland Neoplasms. Neoplasms by Site. Ovarian Diseases. Adnexal Diseases. Genital ... MedlinePlus related topics: Ovarian Cancer Genetic and Rare Diseases Information Center resources: Ovarian Cancer Ovarian ... Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study (MISSION). The safety and scientific ... Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Am J Obstet ...
Find out information about Ovarian neoplasms. Of or pertaining to the ovaries Explanation of Ovarian neoplasms ... ovarian. (redirected from Ovarian neoplasms). Also found in: Dictionary, Medical.. Related to Ovarian neoplasms: ovarian tumors ... Benign teratomas represent about a quarter of all ovarian neoplasms.. Understanding ovarian germ cell neoplasms ... Ovarian neoplasms , Article about Ovarian neoplasms by The Free Dictionary https://encyclopedia2.thefreedictionary.com/Ovarian+ ...
Not all neoplasms represent cancer, and some have overlapping sonographic characteristics. Heres what you need to know to ... Although ovarian cancer is rare, affecting 30 to 50 women of every 100,000, it is particularly deadly, with a 5-year survival ... FIGURE 4E shows how the vascularity and volume of an ovarian mass are calculated, with 3D angiographic display of the blood ... The lifetime risk of ovarian cancer in a woman who has no affected relative is 1.4% (1 case in every 70 women). When the ...
Patient for Mucinous Cystic Neoplasm with Ovarian Struma: a Case Report. Background: Mucinous cystic neoplasms of the pancreas ... The presence of ovarian struma and lack of communication with the main pancreatic duct is required for the diagnosis of ... Conclusion: To our knowledge, this is the first report of an HIV + patient with a mucinous cystic neoplasm and robotic ... mucinous cystic neoplasm.. Case history: We report on a twenty six year old female, with a past medical history significant for ...
Eighty five ovarian epithelial and non-epithelial tumours were studied by peroxidase histochemical staining for their ...
HE 4 (proteina epididimala umana 4) este o proteina ce face parte din familia proteinelor acide din zer al caror miez contine 4 legaturi disulfidice (WFDC= whey acidic four-disulfide core) si care se presupune ca are proprietati inhibitorii asupra tripsinei. A fost identificata initial in epiteliul epididimului distal si i-a fost atribuit rolul de inhibitor de proteaza
Primary appendiceal malignant neoplasms may mimic advanced-stage ovarian cancer and can be misdiagnosed because of its ... Primary appendiceal malignant neoplasms may mimic advanced-stage ovarian cancer. To our knowledge, preoperative diagnosis has ... Primary appendiceal malignant neoplasms may mimic advanced-stage ovarian cancer and, therefore, may be misdiagnosed. In ... Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. ...
The aim of this study was to compare the promoter hypermethylation profiles of ovarian epithelial neoplasms to better ... Ovarian carcinomas are believed to arise de novo from surface epithelium, but the actual molecular pathogenesis is unknown. ... Promoter hypermethylation profile of ovarian epithelial neoplasms. https://edrn.nci.nih.gov/data-and-resources/publications/ ... Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas. ...
Melan A and CD99 may also be positive in ovarian sex cord‐stromal tumours,35,36,37,38 and 1 and 2 of our neoplasms respectively ... Figure 1​1 illustrates examples of the histology of the neoplasms.. Figure 1. Uterine tumour resembling ovarian sex cord tumour ... Pelkey T J, Frierson H F, Jr, Mills S E. et al The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol ... Yao D X, Soslow R A, Hedvat C V. et al Melan‐A (A103) and inhibin expression in ovarian neoplasms. Appl Immunohistochem Mol ...
This report is suggestive of left sided ovarian neoplasm which has grown a lot and thus needs immediate removal. This ... ovarian neoplasm, surgical removal required Detailed Answer: Hello mam, thanks for trusting health care magic. ... Suggest treatment for ovarian neoplasm Brief Answer: ovarian neoplasm, surgical removal required Detailed Answer: Hello mam, ... ovarian neoplasm, surgical removal required. Detailed Answer:. Hello mam, thanks for trusting health care magic.. This report ...
Teh, M., Lee, Y.S. (1996). An immunohistochemical study of p53 protein in ovarian mucinous neoplasms. Pathology 28 (3) : 217- ...
... we think that the neoplasms most likely represent primary ovarian paragangliomas. Because various neoplasms in the sex cord- ... Paraganglioma of the Ovary: Report of Three Cases of a Rare Ovarian Neoplasm, Including Two Exhibiting Inhibin Positivity. ... Immunohistochemically, all neoplasms were cytokeratin negative and diffusely positive with neuroendocrine markers. In 1 case, ... Paraganglioma is one of the rarest neoplasms to involve the ovary, whether primary or metastatic, with only two previous ...
Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms ... borderline and malignant ovarian mucinous neoplasms. We analyzed 41 cases of malignant, 10 cases of borderline, 7 cases of ... In conclusion, Kras mutation appears to be one of the imperative events in the ovarian mucinous adenoma-borderline tumor- ... Kras mutation is a common phenomenon in many human neoplasms. We aimed to assess the Kras mutational status along the ...
Build: Mon Nov 12 13:52:52 EST 2018 (commit: 8a5bcf7). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
Build: Sat Feb 17 08:59:16 EST 2018 (commit: 16064c5). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
Malignant Ovarian Surface Epithelial-Stromal Neoplasm: Read more about Symptoms, Diagnosis, Treatment, Complications, Causes ...
... and malignant ovarian neoplasms. Together they form a unique fingerprint. * Ovarian Neoplasms Medicine & Life Sciences ... NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Barry M. Kacinski, Allan G. Mayer, Bonnie L ... NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecologic Oncology. 1992;44(3):245-253. ... NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. / Kacinski, Barry M.; Mayer, Allan G.; King ...
Mucinous ovarian tumors (MOT) are among the rarest and least studied epithelial ovarian neoplasms. Teratoma-associated MOT have ... 1591P - Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors ... Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors ... 13 high-grade serous ovarian carcinomas (HGSOC), 6 ovarian surface epithelium (OSE), 2 human PGCs and single cell RNA- ...
... to differentiate ovarian cancer from benign or borderline ovarian tumors. In ovarian cancer high Ang-2/sVEGFR-2 ratio was ... The serum level of Ang-2 predicted most accurately poor OS and Ang-2/sVEGFR-2 ratio malignancy of ovarian neoplasms and short ... We enrolled 132 patients with ovarian neoplasms and 32 unaffected women in this study. Serum samples were collected ... benign and/or borderline ovarian neoplasms. In ROC analysis, the area under the curve for serum Ang-2/sVEGFR-2 ratio (0.76) was ...
Ovarian Neoplasms -- Autobiography Resource Information The concept Ovarian Neoplasms -- Autobiography represents the subject, ... Ovarian Neoplasms -- Autobiography. Authority link http://www.ncbi.nlm.nih.gov/mesh/?term=D010051. Focus * Ovarian Neoplasms ... Context of Ovarian Neoplasms -- Autobiography Subject of. * A feather in my wig : ovarian cancer cured : twelve years and going ... Data Citation of the Concept Ovarian Neoplasms -- Autobiography. Copy and paste the following RDF/HTML data fragment to cite ...
Asymptomatic premenopausal patients with simple ovarian cysts , 10 cm in diameter can be observed or placed on suppressive ...
  • The words "neoplasm" and "tumor" are often used interchangeably, but not all neoplasms are tumors . (wisegeek.com)
  • Immunohistochemical analysis using monoclonal antibodies against smooth muscle actin (SMA) and CD34 (an endothelial cell marker) demonstrated that low resistance to blood flow in vessels within malignant ovarian tumors may be associated with a poorly developed muscular coat in the tumor vessels, compared with that observed in benign tumors. (knowcancer.com)
  • The difference in the angiogenic and vascular resistant natures of benign and malignant ovarian tumors showing intratumoral blood flow may thus be correlated with the endothelial cell activity of the tumor vessels and not the MVD. (knowcancer.com)
  • Spherical tissue sampling in 3-dimensional power Doppler angiography: a new approach for evaluation of ovarian tumors. (mdedge.com)
  • The differential is broad and may include many other ovarian tumors, particularly those with an oxyphilic cell type. (ovid.com)
  • We analyzed 41 cases of malignant, 10 cases of borderline, 7 cases of benign mucinous ovarian tumors and 7 cases of normal ovarian tissue. (oncotarget.com)
  • The expression of α-SMA and PCNA were calculated in cells and stroma of ovarian tumors. (waocp.org)
  • Complications of presumed benign ovarian tumors]. (nih.gov)
  • Ovarian tumors are unusual lesions in the pediatric population. (elsevier.com)
  • Whereas most ovarian tumors in girls are benign, some children have malignant tumors that are very aggressive and do not respond well to adjuvant therapy. (elsevier.com)
  • Medical records of 84 women of reproductive age (15-45 years) with histologically confirmed early-stage (IA-IIC) borderline ovarian tumors or cancers who had undergone conservative surgery between January 2003 and December 2012 were retrospectively reviewed. (waocp.org)
  • Histologically, 30 (35.7%) had borderline ovarian tumors, 28 (33.3%) epithelial cancers, 22 (26.2%) malignant germ cell tumors, and 4 (4.8%) sex cord stromal tumors. (waocp.org)
  • Twenty cases of ovarian neoplasm (12 non-coelomic and 8 coelomic and 8 epithelial tumors) have been subjected to fine needle aspiration biopsy (FNAB). (who.int)
  • Cytological features of different groups of ovarian tumors are to some extent characteristic. (who.int)
  • Her-2/neu amplification was restricted to carcinomas and was not encountered in ovarian borderline tumors. (elsevier.com)
  • It has mostly been studied in women with ovarian cancer or tumors which are not very aggressive. (steadyhealth.com)
  • Introduction: Primary ovarian neoplasms exhibit a wide range of histopathological aspects, and tumors with epithelial differentiation are the most frequent. (ufrgs.br)
  • Method: Sixty distinct cases of primary ovarian tumors were selected, previously analyzed at the Laboratory of Pathology of the Hospital Complex of Universidade Luterana do Brasil (Ulbra), between 2005 and 2010, from patients undergoing concomitant analysis of CA 125. (ufrgs.br)
  • Conclusion: In the present study, serum levels of CA 125 were associated with histological grade in primary ovarian neoplasms, especially in high-grade malignant tumors, suggesting that high levels of this glycoprotein are associated with lesions of more aggressive biological behavior. (ufrgs.br)
  • In performing these analyses, we assumed that women who developed ovarian cancer during the first half were more likely to have undiagnosed tumors in an advanced stage of progression at the time of dietary assessment than those women who developed ovarian cancer with longer follow-up, and that the timing of higher folate intake could be related to tumor progression or prevention as reported elsewhere ( 6 ). (aacrjournals.org)
  • Cytoskeleton intermediate filament composition of ovarian tissues indicates that the cytokeratin and vimentin are observed in ovarian surface epithelium along with the common ovarian epithelial tumors. (iranpath.org)
  • The current study aimed at investigating the cytokeratin and vimentin expression in epithelial ovarian tumors to establish a diagnostic relevance. (iranpath.org)
  • All ovarian epithelial tumors expressed cytokeratin in a uniform fashion. (iranpath.org)
  • Riccardi E, Grieco V, Verganti S, Finazzi M. Immunohistochemical diagnosis of canine ovarian epithelial and granulosa cell tumors. (iranpath.org)
  • Intermediate filaments cytokeratin and vimentin in ovarian sex cord-stromal tumors with correlative studies in adult and fetal ovaries. (iranpath.org)
  • Mucinous ovarian tumors represent a distinct histotype of epithelial ovarian cancer. (biomedcentral.com)
  • We undertook hotspot sequencing of 50 genes commonly mutated in human cancer across 69 mucinous ovarian tumors. (biomedcentral.com)
  • Ovarian tumors secreting androgens: an infrequent cause of hyperandrogenism. (bioportfolio.com)
  • The sex cord-stromal tumors are relative rare, comprising 5-8% of all ovarian neoplasms. (bioportfolio.com)
  • Brenner tumors are uncommon ovarian neoplasms which occasionally occur in combination with a mucinous tumor. (bioportfolio.com)
  • Pathology and classification of ovarian tumors. (msjonline.org)
  • Distribution of various histopathological types of ovarian tumors: A study of 212 cases from a tertiary care center of Eastern Uttar Pradesh. (msjonline.org)
  • Intra-operative cytology of ovarian tumors. (msjonline.org)
  • OBJECTIVE: To critically review the published literature regarding the proposed association of ovarian stimulation and increased risk of ovarian tumors. (biomedsearch.com)
  • Primary Ovarian Tumors With Lymphogenic and Hematogenic Metastasis Express High MMP-14, Which Colocalizes With Highly Sulfated Chondroitin Sulfate in the Stroma. (amedeo.com)
  • Most malignant ovarian tumors occur in girls aged 15 to 19 years. (cancer.gov)
  • Morowitz M, Huff D, von Allmen D: Epithelial ovarian tumors in children: a retrospective analysis. (cancer.gov)
  • Pediatric ovarian tumors: a review of 67 cases. (cancer.gov)
  • Ovarian epithelial tumors of low malignant potential: a case series of 5 adolescent patients. (cancer.gov)
  • A population-based analysis of 1037 malignant ovarian tumors in the pediatric population. (cancer.gov)
  • Most ovarian tumors in the pediatric age range are benign and borderline,[ 1 ] with rare malignant lesions in adolescence. (cancer.gov)
  • Although this neoplasm only makes up a small proportion of the cases of malignancies diagnosed in the country, at the moment, it has the second highest mortality rate for all gynecological tumors 2 . (scielo.br)
  • Krukenberg tumors are metastatic ovarian neoplasms from primary lesions inthe gastrointestinal tract. (ispub.com)
  • Rare cases of Krukenberg tumor from early gastric cancers have however been reported in the literature [ 2 ] and sometimes these tumors have been detected even before the diagnosis of the primary neoplasm. (ispub.com)
  • Diagnosis is usually made by ultrasonography showing a solid ovarian lesion, or, on some occasions, mixed tumors with solid and cystic components. (wikipedia.org)
  • Prospective randomized phase IV study aimed to value the impact of diaphragmatic surgery and the useful of intra-operatory thoracic drain in advanced ovarian cancer. (clinicaltrials.gov)
  • The aim of this prospective Phase II multicentric study is to assess feasibility and early complications rate of 'total laparoscopic/robotic' interval debulking surgery in patients with a clinical complete/partial response to neoadjuvant chemotherapy for advanced ovarian cancer. (clinicaltrials.gov)
  • To compare paclitaxel in combination with carboplatin versus a control treatment of either single-agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin) as first-line treatment of patients with advanced ovarian cancer. (isrctn.com)
  • The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer. (clinicaltrials.gov)
  • Conclusions Minimally invasive surgery may be considered for the management of patients with advanced ovarian cancer who have undergone neoadjuvant chemotherapy, when surgery is limited to low-complexity standard cytoreductive procedures. (bmj.com)
  • Interval cytoreduction for advanced ovarian cancer: is minimally invasive surgery ready for the next prospective randomized trial? (bmj.com)
  • BACKGROUND: Previous studies have established that soluble interleukin-2 receptor alpha (sIL-2R alpha) levels are elevated in ascites and sera from individuals with advanced ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] Stage III/IV). (duke.edu)
  • A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. (amedeo.com)
  • RR = 4.47 for OS) are the prognostic factors on the 56 ovarian carcinoma patients by multivariate analyses. (nih.gov)
  • RR = 5.37 for OS) are the prognostic factors for 40 ovarian carcinoma patients with residual disease less than 2 cm by multivariate analyses. (nih.gov)
  • Mucinous ovarian neoplasms are usually negative for gross cystic disease fluid protein 15 (GCDFP-15) and transcription factor GATA-binding protein 3 (GATA-3), whereas the reverse is true for metastatic carcinoma. (thefreedictionary.com)
  • In conclusion, Kras mutation appears to be one of the imperative events in the ovarian mucinous adenoma - borderline tumor - carcinoma sequence, as increased numbers of Kras mutations have been shown to be the strongest predictor of unequivocal malignancy in ovarian mucinous neoplasms. (oncotarget.com)
  • The overexpressions of α-SMA in tumor cells were only detected in serous and clear cell ovarian carcinoma. (waocp.org)
  • Tumor cells of serous and clear cell ovarian carcinoma exhibit mesenchymal characteristic as shown by α-SMA positive expression. (waocp.org)
  • Epithelial Cell Ovarian Carcinoma are derived from mesothelial cells. (dokita.ng)
  • High-grade serous ovarian carcinoma (HGSOC) is the most common Type II tumour, accounting for almost 75% of all EOCs. (dokita.ng)
  • 1-3 Both ovarian clear cell carcinoma and endometrioid carcinoma are often associated with endometriosis, 4-6 sharing similar histogenesis and pathogenesis, 7 and are known as endometriosis-associated ovarian cancer. (bmj.com)
  • We analyzed serial frozen tissue sections from 26 patients with epithelial ovarian carcinoma and 10 patients with benign cystadenoma of ovary for Elf-1 protein expression, using fluorescent immunohistochemistry. (nih.gov)
  • There was, however, abundant Elf-1 immunoreactivity in the nucleus of the ovarian carcinoma cells along with a little cytoplasmic staining. (nih.gov)
  • Our results demonstrate that Elf-1 expression in ovarian carcinoma correlates with the malignant potential of this tumor. (nih.gov)
  • Given the spectrum of RAS-activating mutations, it is clear that targeting this pathway may be a viable therapeutic option for patients with recurrent or advanced stage mucinous ovarian carcinoma, however caution should be exercised in selecting one or more personalized therapeutics given the frequency of non-redundant RAS-activating alterations. (biomedcentral.com)
  • We report a very uncommon case because of the presentation of ovarian carcinoma as cutaneous metastasis. (scielo.br)
  • Ovarian carcinoma is the third most common gynecological cancer and it remains the leading cause of death among women who develop cancers of gynecologic origin. (scielo.br)
  • Sister chromatid exchange (SCE) frequencies were studied in normal and mutagen-treated lymphocyte cultures from patients with ovarian carcinoma and controls. (biomedsearch.com)
  • Cellular kinetics, expressed as average generation time (AGT), was suppressed in lymphocyte cultures from ovarian carcinoma patients as compared to the controls (p much less than 0.05). (biomedsearch.com)
  • It was concluded that although baseline SCE rates in lymphocytes of patients with ovarian carcinoma were higher as compared to the controls, they have very limited application as a marker malignancy. (biomedsearch.com)
  • Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma. (amedeo.com)
  • Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma. (amedeo.com)
  • Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. (amedeo.com)
  • Girls with ovarian carcinoma (epithelial ovarian neoplasia) fare better than do adults with similar histology, probably because girls usually present with low-stage disease. (cancer.gov)
  • Hereditary breast and ovarian cancer syndrome, which is related to mutations in the BRCA1 and BRCA2 genes, is an important cause of ovarian carcinoma. (scielo.br)
  • Because of the strong association between ovarian carcinoma and germline mutation, different professional bodies have recommended counselling and genetic testing for any woman who develops a malignant tumor 7 , 8 . (scielo.br)
  • Understanding the Value of Tumor Markers in Pediatric Ovarian Neoplasms. (nih.gov)
  • The purpose of this study was to determine the diagnostic accuracy of tumor markers for malignancy in girls with ovarian neoplasms. (nih.gov)
  • Tumor marker testing is helpful in preoperative risk stratification of ovarian neoplasms for malignancy. (nih.gov)
  • Granulosa cell cancer constitutes less than 5% of ovarian neoplasms (commonest malignant sex cord-stromal tumor) seen in postmenopausal women. (thefreedictionary.com)
  • G. Relationship between the vascular right ovary and the uterus.Tumor vascularity is another marker suggestive of ovarian malignancy ( FIGURE 4C and 4D ). (mdedge.com)
  • She subsequently received a diagnosis of primary pseudomyxoma peritonei metastatic to the ovaries, mimicking a primary ovarian cancer by osteopathic structural examination findings, serum tumor markers, surgical exploration, and histopathologic confirmation. (jaoa.org)
  • In situ hybridization (ISH) analysis of 24 benign, borderline, and malignant ovarian tumor specimens revealed NEU transcript expression by epithelial elements in approximately two-thirds of the samples and high-level expression in 3 grade 3 adenocarcinomas. (elsevier.com)
  • The aim of this research was to analyse the characteristic of α-SMA and collagen in tumor cells and stroma of ovarian neoplasms. (waocp.org)
  • Ovarian torsion of mixed epithelial tumor misdiagnosed as a malignancy in postmenopausal woman: A case report. (nih.gov)
  • Objective Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. (bmj.com)
  • This study investigated the significance of preoperative tumor markers and clinical characteristics in distinguishing endometriosis-related ovarian neoplasms from ovarian endometrioma. (bmj.com)
  • Age, tumor size, and the presence of mural nodule were important factors in the preoperative prediction of endometriosis-related ovarian neoplasms. (bmj.com)
  • FDA-approved IHC and FISH for Her-2/neu were performed on formalin-fixed, paraffin-embedded tissue from 79 ovarian neoplasms representing a broad spectrum of tumor types as well as four normal ovaries. (elsevier.com)
  • The primary purpose of this Phase 3 study is to compare the efficacy and safety of rucaparib versus chemotherapy as treatment for relapsed ovarian cancer in patients with a deleterious BRCA1/2 mutation in their tumor. (clinicaltrials.gov)
  • Overall, the prevalence of RAS-alteration and striking co-occurrence of pathway "double-hits" supports a critical role for tumor progression in this ovarian malignancy. (biomedcentral.com)
  • When present, skin metastases of ovarian cancer are usually localized in the vicinity of the primary tumor. (scielo.br)
  • Ovarian Combined Brenner Tumor, Mucinous Cystadenoma and Struma Ovarii: First Report of a Rare Combination. (bioportfolio.com)
  • Aims and objectives is to study the histopathological parameters of ovarian tumor. (msjonline.org)
  • A total 612 cases of ovarian tumor were included for study. (msjonline.org)
  • The high incidence of malignant ovarian tumor with late presentation was observed in our study. (msjonline.org)
  • Tumor-to-Tumor Metastasis of Colorectal Adenocarcinoma to Ovarian Cystadenofibroma: A Case Report and Review of the Literature. (amedeo.com)
  • Ovarian Sclerosing Stromal Tumor and Mullerian Cyst in an 11-yr-old Girl: A Case Report and Review of the Literature. (amedeo.com)
  • Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies. (amedeo.com)
  • Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review. (cancer.gov)
  • A neoplasm in which the tumor cells are confined by the basement membrane to the epithelium of origin. (utah.edu)
  • We discuss the CT appearance of a metastatic ovarian tumor from an advanced gastric cancer with a review of the literature. (ispub.com)
  • Moreover a 3.5 cm enhancing solid mass was visualized in the left adnexa representing an ovarian metastasis, also known as Krukenberg tumor (Fig. 1c). (ispub.com)
  • The term Krukenberg tumor, from its eponymic description [ 1 ], refers to ovarian lesions with sarcomatous stroma and mucin-containing signet-ring cells. (ispub.com)
  • Confident distinction between primary and metastatic ovarian cancers is not possible in many cases because of overlapping imaging findings, however bilateral, sharply delineated, purely solid or predominantly solid lesions with necrosis favors the diagnosis of a metastatic ovarian tumor. (ispub.com)
  • The surgeon usually attempts to excise the neoplasm while leaving the ovary itself intact, if possible, as removing the ovaries results in infertility and causes hormonal problems with significant negative effects on health, particularly in premenopausal women. (wisegeek.com)
  • Specific sonographic findings reported for birds with ovarian neoplasms include massive enlargement of the ovary with well-defined structures appearing as large rounded masses of mixed echogenicity. (thefreedictionary.com)
  • Impression- Multiseptated large cystic lesion seen pelvis with left ovary not visualised separatly from this lesion - suggestive of cystic ovarian neoplasm . (healthcaremagic.com)
  • Paraganglioma is one of the rarest neoplasms to involve the ovary, whether primary or metastatic, with only two previous reports. (ovid.com)
  • Although metastatic spread from an undetected primary outside the ovary cannot be totally excluded for the 2 cases with extraovarian disease, we think that the neoplasms most likely represent primary ovarian paragangliomas. (ovid.com)
  • Possible theories of histogenesis of primary ovarian paraganglioma include an origin from extra-adrenal paraganglia in the region of the ovary or unidirectional differentiation within a teratoma. (ovid.com)
  • The prevalence of Kras mutations in the normal ovary was 0.00% ( n =0/7), while the prevalence in benign, borderline and malignant mucinous neoplasms was 57.14% ( n =4/7), 90.00% ( n =9/10) and 75.61% ( n =31/41), respectively. (oncotarget.com)
  • Malignant Ovarian Neoplasms begins with differentiation of the cells overlying the ovary. (dokita.ng)
  • Sasano, H 1994, ' Functional pathology of human ovarian steroidogenesis: Normal cycling ovary and steroid-producing neoplasms ', Endocrine Pathology , vol. 5, no. 2, pp. 81-89. (elsevier.com)
  • Pelvic magnetic resonance imaging suggested tamoxifen -associated endometrial and ovarian changes, especially a 4.1x3.4-cm-sized, well-defined, multicystic mass in the right ovary . (bvsalud.org)
  • We have postulated that ovarian mesothelial cells may be influenced by underlying growth signals based on the observation of highly polarized DNA synthesis and morphogenesis in the postovulatory rabbit ovary (5). (springer.com)
  • A malignant ovarian neoplasm, or ovarian cancer, is also treated surgically, sometimes in combination with other treatments. (wisegeek.com)
  • Chemotherapy for ovarian cancer usually involves a combination of drugs that are administered by injection, either into the bloodstream or directly into the abdomen. (wisegeek.com)
  • Ovarian cancer represents the leading cause of death from gynecologic malignancies. (clinicaltrials.gov)
  • 5 cm) diaphragmatic peritonectomy/resection in the ovarian cancer debulking. (clinicaltrials.gov)
  • Sample size is composed by 44 Patients affected by advanced stage ovarian cancer, meeting inclusion criteria, undergo diaphragmatic surgery followed by intra-operatory thoracic drain position and 44 patients with same characteristics undergo to diaphragmatic surgery without intra-operatory thoracic drain position. (clinicaltrials.gov)
  • To investigate the relationship between serum vascular endothelial growth factor (VEGF) and clinicopathological factors and to determine whether VEGF is an independent prognostic factor of ovarian cancer patients. (nih.gov)
  • Fifty-six women with International Federation of Gynecology and Obstetrics stages I to IV epithelial ovarian cancer undergoing surgery were enrolled. (nih.gov)
  • The median VEGF serum level in ovarian cancer patients was 458.7 pg/mL. (nih.gov)
  • Pretreatment VEGF serum levels might be regarded as an additional factor in predicting the outcome of ovarian cancer patients. (nih.gov)
  • Anti-angiogenic therapy, if is available, might be a new treatment modality for ovarian cancer patients with poor prognosis predicted by VEGF and other clinical parameters. (nih.gov)
  • Ovarian cancer is the second most common gynecologic malignancy, and the leading cause of cancer related death among the gynecologic malignancies. (knowcancer.com)
  • It is estimated that 23,300 new cases of ovarian cancer will be diagnosed in the United States in 2003 and that 13,900 women will die from disease. (knowcancer.com)
  • Angiogenesis may serve as a prognostic indicator in ovarian cancer. (knowcancer.com)
  • Angiostatin and endostatin have also been found to inhibit ovarian cancer growth in mice 7. (knowcancer.com)
  • The neovascularization required of fast growing malignancies in general, and ovarian cancer specifically, necessitates that they contain many new vessels that have less smooth muscle in their walls. (knowcancer.com)
  • Ovarian neoplasms constitute 25% of all gynecologic tumours in most developed countries and is the 2nd commonest malignancy of the female genital tract following endometrial cancer. (thefreedictionary.com)
  • The fifth leading cause of cancer-related deaths among women in the United States is ovarian cancer. (jaoa.org)
  • More than two-thirds of cases of ovarian cancer are diagnosed at stage III or IV when the peritoneal cavity or other organs are affected. (jaoa.org)
  • Primary appendiceal malignant neoplasms may mimic advanced-stage ovarian cancer and can be misdiagnosed because of its presentation as a palpable adnexal mass. (jaoa.org)
  • The authors describe a 42-year-old woman who was admitted to the department of obstetrics and gynecology to receive treatment for presumed advanced-stage ovarian cancer. (jaoa.org)
  • Ovarian cancer is the fifth leading cause of cancer-related deaths among US women, with an estimated 21,980 new cases and 14,270 deaths nationwide in 2014. (jaoa.org)
  • 5 Elevated biomarkers, such as carcinoembryonic antigen and cancer antigen 125, have limited use in diagnosing ovarian cancer. (jaoa.org)
  • We present the case of a woman with primary pseudomyxoma peritonei (PMP) mimicking advanced-stage ovarian cancer. (jaoa.org)
  • Yes it can be ovarian cancer . (healthcaremagic.com)
  • A feather in my wig : ovarian cancer cured : twelve years and going strong! (bu.edu)
  • Histochemical and Immunohistochemical Study of α-SMA, Collagen, and PCNA in Epithelial Ovarian Neoplasm', Asian Pacific Journal of Cancer Prevention , 18(3), pp. 667-671. (waocp.org)
  • Less than 30% of women with advanced stage ovarian cancer survive long-term. (dokita.ng)
  • When ovarian cancer is diagnosed in stage I, up to 90% of patients can be cured with conventional surgery and chemotherapy. (dokita.ng)
  • 2 Malignant Ovarian neoplasm represents the sixth most commonly diagnosed cancer among women in the world despite the high incidence and fatality rates. (dokita.ng)
  • Established risk factors for ovarian cancer include age and having a family history of the disease, while protective factors include increasing parity, oral contraceptive use, and oophorectomy. (dokita.ng)
  • Ovarian cancer has a wide range difference in incidence by race. (dokita.ng)
  • 2 Recent studies shows a link between ovarian cancer and endometriosis due to the up regulation of chronic activation of complement pathway in women with endometriosis. (dokita.ng)
  • Endometriosis may be associated with a subset of histologic subtypes of ovarian cancer. (bmj.com)
  • Pregnancy Outcomes after Conservative Surgery for Early-Stage Ovarian Neoplasms', Asian Pacific Journal of Cancer Prevention , 18(8), pp. 2083-2087. (waocp.org)
  • Therapeutic progress in ovarian cancer, testicular cancer and the sarcomas / edited by A. T. van Oosterom, F. M. Muggia, F. J. Cleton. (who.int)
  • Ovarian cancer : screening, treatment, and followup. (who.int)
  • Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. (isrctn.com)
  • An economic model from the Spanish hospitals perspective was constructed to compare the costs derived from the treatment using both drugs in patients with recurrent epithelial ovarian cancer who failed a first-line platinum-containing regimen. (nature.com)
  • These findings suggest that pegylated liposomal doxorubicin hydrochloride is an efficient therapy and can be used as a cost-saving option for treatment of patients with recurrent epithelial ovarian cancer who have failed a first-line platinum-containing regimen. (nature.com)
  • Ovarian cancer is the sixth most common form of cancer worldwide and is the leading cause of cancer deaths of the gynaecological tumours ( Landis et al, 1998 ). (nature.com)
  • Due to the often asymptomatic nature of the early stages of disease, many cases of ovarian cancer have a very poor diagnosis and are not detected until the advanced stages, which suggest that a low survival rate since 5-year survival rates for women in advanced stages of the disease are only around 30% ( Gore, 1999 , pp 76-90). (nature.com)
  • Topotecan (T) is a topoisomerase I inhibitor approved in Europe for the treatment of metastatic ovarian cancer after failure of first-line or for subsequent retreatment. (nature.com)
  • Dermoid cysts are ovarian cysts found during pregnancy that are larger than five centimetres and very rarely lead to ovarian cancer. (steadyhealth.com)
  • The sooner ovarian cancer is found and treated, the better your chance for recovery. (medlineplus.gov)
  • But ovarian cancer is hard to detect early. (medlineplus.gov)
  • Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. (medlineplus.gov)
  • To diagnose ovarian cancer, doctors do one or more tests. (medlineplus.gov)
  • What Is Ovarian Cancer? (medlineplus.gov)
  • Can Ovarian Cancer Be Found Early? (medlineplus.gov)
  • How Is Ovarian Cancer Diagnosed? (medlineplus.gov)
  • Can Ovarian Cancer Be Prevented? (medlineplus.gov)
  • What Are the Risk Factors for Ovarian Cancer? (medlineplus.gov)
  • What Will Happen After Treatment for Ovarian Cancer? (medlineplus.gov)
  • This is a Phase IB non-randomized, single-arm, open-label study of atezolizumab in combination with primary NACT-ICS in patients with advanced-stage epithelial ovarian cancer. (clinicaltrials.gov)
  • The target population is women with previously untreated epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) with advanced stage (FIGO III-IV) disease suitable for NACT and ICS. (clinicaltrials.gov)
  • The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy. (clinicaltrials.gov)
  • Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). (clinicaltrials.gov)
  • While PARP inhibitors have demonstrated consistent robust clinical activity in patients with relapsed ovarian cancer associated with HRD, prospective studies evaluating efficacy and safety of PARPi versus standard of care chemotherapy have been limited. (clinicaltrials.gov)
  • A 66-year-old postmenopausal woman , who had received left partial mastectomy due to breast cancer (about 4 years ago) and was taking tamoxifen treatment , had an ovarian cyst on ultrasonography . (bvsalud.org)
  • Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. (hopkinsmedicine.org)
  • Recurrent, histologically proven, platinum-resistant, epithelial ovarian, fallopian tube and primary peritoneal cancer in advanced or metastatic stage. (who.int)
  • Seven centers confirmed and five were included, with a total of 127 patients diagnosed with advanced epithelial ovarian cancer after neoadjuvant chemotherapy and minimally invasive interval surgery. (bmj.com)
  • Folate receptor α (FRα) expression in epithelial ovarian cancer may be related to folate intake. (aacrjournals.org)
  • The association of multivitamin intake with ovarian cancer may depend on FRα expression level. (aacrjournals.org)
  • Ovarian cancer is the leading cause of mortality among cancers specific to women in the United States ( 1 ). (aacrjournals.org)
  • Few epidemiologic factors for ovarian cancer are recognized: age, a family history of ovarian or breast cancer, and nulliparity are associated with increased risk, whereas oral contraceptive use is associated with decreased risk ( 2 , 3 ). (aacrjournals.org)
  • These variables, along with a low intake of green vegetables and a high dietary fat score, explained only 50% of ovarian cancer risk in an Italian population ( 4 ), highlighting the need to further identify factors associated with the development and progression of this debilitating and often fatal cancer. (aacrjournals.org)
  • Histological classification of ovarian cancer.Med Electron Microsc.2003;36(1):9-17. (iranpath.org)
  • Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. (duke.edu)
  • This study was undertaken to evaluate sIL-2R alpha levels in individuals with benign ovarian neoplasms and early stage ovarian cancer (FIGO Stage I/II). (duke.edu)
  • RESULTS: The mean serum sIL-2R alpha levels for benign pelvic masses, and Stage I/II and Stage III/IV epithelial ovarian cancer were 1507 +/- 82, 1631 +/- 274, and 2596 +/- 384 U/ml, respectively. (duke.edu)
  • In addition, of the four individuals with FIGO Stage I/II ovarian cancer who had CA125 levels below 35 U/ml, the accepted upper limit of normal, three patients had elevated serum sIL-2R alpha levels. (duke.edu)
  • however, measurement of sIL-2R alpha levels in combination with CA125 warrants further evaluation to determine if together they will identify individuals with Stages I and II ovarian cancer. (duke.edu)
  • Metastatic ovarian cancer uncommonly presents with skin metastasis. (scielo.br)
  • According to the staging system of the International Federation of Gynecology and Obstetrics (FIGO) it was considered a stage IV ovarian cancer. (scielo.br)
  • The primary objective of this study is to estimate the Progression Free Survival Rates (PFS) of patients with relapsed ovarian cancer after 9 months of continuous treatment with either BIB. (bioportfolio.com)
  • Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. (bioportfolio.com)
  • Ovarian cancer is the second most common gynaecologic malignancy and the main cause of death from gynaecologic cancer, due to late diagnosis and chemoresistance. (bioportfolio.com)
  • An ovarian cyst can be benign but sometimes a septated cystic structure could mean cancer . (healthtap.com)
  • Ovarian cancer is the leading cause of cancer related death amongst women in India. (msjonline.org)
  • This retrospective study was done on patients who presented ovarian mass and subsequently underwent surgery in a Regional Cancer Centre, Odisha, over a period of three years from January 2016 to December 2018. (msjonline.org)
  • CA-125 is a protein that is found more in ovarian cancer cells than in other cells. (medlineplus.gov)
  • This blood test is often used to monitor women who have been diagnosed with ovarian cancer . (medlineplus.gov)
  • In these cases, measuring the CA-125 over time is a good tool to determine if ovarian cancer treatment is working. (medlineplus.gov)
  • The CA-125 test may also be done if a woman has symptoms or findings on ultrasound that suggest ovarian cancer. (medlineplus.gov)
  • In general, this test is not used to screen healthy women for ovarian cancer when a diagnosis has not yet been made. (medlineplus.gov)
  • In a woman who has ovarian cancer, a rise in CA-125 usually means that the disease has progressed or come back (recurred). (medlineplus.gov)
  • In a woman who has not been diagnosed with ovarian cancer, a rise in CA-125 may mean a number of things. (medlineplus.gov)
  • While it may mean that she has ovarian cancer, it can also indicate other types of cancer, as well as several other diseases, such as endometriosis, which are not cancer. (medlineplus.gov)
  • In healthy women, an elevated CA-125 usually does not mean ovarian cancer is present. (medlineplus.gov)
  • Most healthy women with an elevated CA-125 do not have ovarian cancer, or any other cancer. (medlineplus.gov)
  • Enhancement of lymphocytic SCE frequencies in patients with ovarian cancer. (biomedsearch.com)
  • CONCLUSION: Despite a few studies showing an apparent association between ovulation induction and ovarian cancer, support for their results has not been forthcoming. (biomedsearch.com)
  • Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy. (amedeo.com)
  • Misdiagnosis of High-grade Serous Ovarian Cancer With BRCA Mutation as Endometriotic Cyst Due to Its Unique Gross Morphology: A Case Report and Literature Review. (amedeo.com)
  • Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor. (amedeo.com)
  • Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. (amedeo.com)
  • Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. (amedeo.com)
  • Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. (amedeo.com)
  • Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? (amedeo.com)
  • Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology. (amedeo.com)
  • the one death was not from ovarian cancer. (cancer.gov)
  • Refer to the PDQ summary on adult Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment for more information. (cancer.gov)
  • Šekerija M, Čukelj P. Epidemiology of ovarian cancer in Croatia. (srce.hr)
  • M. Šekerija i P. Čukelj, "Epidemiology of ovarian cancer in Croatia", Libri Oncologici , vol.43, br. (srce.hr)
  • Ovarian cancer is one of the most lethal malignant cancers in women, mainly because of the late stage at diagnosis. (srce.hr)
  • In Croatia, ovarian cancer ranks as the sixth most common cancer in women (430 new cases in 2013) and the sixth malignant cause of death (328 deaths in 2013). (srce.hr)
  • Research based on the Croatian National Cancer Registry data also shows that trends of standardized incidence and mortality rates for ovarian cancer in Croatia are relatively stable for the period from 1988 to 2008, while recent studies oncancer survival (EUROCARE-5, CONCORD-2) rank Croatia close to the European mean when it comes to ovarian cancer survival. (srce.hr)
  • Ovarian cancer is asignifi cant public health burden in Croatia. (srce.hr)
  • To analyze the cost effectiveness of the diagnostic program for the germline mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed with ovarian cancer associated with this mutation. (scielo.br)
  • According to data provided by the National Cancer Institute, around 6,150 new cases of ovarian cancer are recorded every year in Brazil 1 . (scielo.br)
  • Therefore, the objective of this study was to analyze the cost effectiveness of the program for diagnosing the germline mutation in the BRCA1/2 genes and of the preventative strategies offered to the relatives of patients who develop ovarian cancer. (scielo.br)
  • Eighty five ovarian epithelial and non-epithelial tumours were studied by peroxidase histochemical staining for their reactivity with six monoclonal human milk fat globule (HMFG) antibodies, peanut agglutinin (PNA) lectin, and a monoclonal cytokeratin antibody. (bmj.com)
  • Uterine tumours resembling ovarian sex cord tumours (UTROSCTs) are rare primary uterine neoplasms which morphologically resemble ovarian sex cord stromal tumours. (pubmedcentralcanada.ca)
  • Type I neoplasms are now generally referred to as endometrial stromal tumours with sex cord‐like elements while type II tumours are designated UTROSCT. (pubmedcentralcanada.ca)
  • 2 In the latest World Health Organization classification of tumours of the female genital organs, UTROSCT is classified separately to endometrial stromal neoplasms. (pubmedcentralcanada.ca)
  • 2 However, there is ongoing debate as to the exact histogenesis, ie whether they represent variants of endometrial stromal neoplasm or are separate unrelated tumours. (pubmedcentralcanada.ca)
  • Histological typing of ovarian tumours / S. F. Serov, R. E. Scully, in collaboration with L. H. Sobin and pathologists in ten countries. (who.int)
  • Sertoli-Leydig cell tumours (SLCT) are rare tumours, accounting for less than 0.5% among the ovarian tumours, and occur most frequently in the second and third decades. (elsevier.es)
  • Retrospective and prospective study of ovarian tumours and tumour-like lesions. (msjonline.org)
  • Histopathological profile of ovarian tumours: A twelve year institutional experience. (msjonline.org)
  • Ovarian tumours in Africans: a study of 512 cases. (msjonline.org)
  • Swamy GG, Satyanarayana N. Clinicopathological analysis of ovarian tumours-A study on five years samples. (msjonline.org)
  • Ovulation induction and ovarian tumours: the debate continues. (biomedsearch.com)
  • 1. Sladkevicius P, Jokubkiene L, Valentin L. Contribution of morphological assessment of the vessel tree by three-dimensional ultrasound to a correct diagnosis of malignancy in ovarian masses. (mdedge.com)
  • The presence of ovarian struma and lack of communication with the main pancreatic duct is required for the diagnosis of mucinous cystic neoplasm. (sages.org)
  • Martingano D, Gurm H, Oliff A, Martingano FX, Aglialoro G. Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. (jaoa.org)
  • Because various neoplasms in the sex cord-stromal and steroid categories are likely to enter into the differential diagnosis, inhibin and calretinin positivity represents a significant potential diagnostic pitfall. (ovid.com)
  • Hence, an attempt has been made in the present study to evaluate the current status of Image-directed percutaneous needle aspiration in ovarian neoplasms and to assess its value and limitations in the diagnosis and management of ovarian neoplasms. (who.int)
  • Considering the rapidity and reliability of the procedure with its added advantages like cost-effectiveness and increased patient acceptability, it can be concluded that image-guided FNAC holds a key position in the diagnosis and management of ovarian neoplasms. (who.int)
  • In eight cases of non coelomic epithelial neoplasms preoperative cytological diagnosis helped in conservative surgery. (who.int)
  • In another series of 19 patients younger than 21 years with epithelial ovarian neoplasms, the average age at diagnosis was 19.7 years. (cancer.gov)
  • differential diagnosis can be achieved analyzing the relationships between the lesion and the pelvic ureter and the course of the ovarian vein. (ispub.com)
  • In the first trimester of pregnancy, some women may develop ovarian cysts which are found on routine ultrasound examination of the developing fetus. (steadyhealth.com)
  • Ovarian cysts that are noted during the first trimester usually resolve on their own by the beginning of the second trimester. (steadyhealth.com)
  • Having a history of previous ovarian cysts. (steadyhealth.com)
  • The ovarian fibroma, also fibroma, is a benign sex cord-stromal tumour. (wikipedia.org)
  • Methods A case-control study was conducted on 283 women who were diagnosed with confirmed pathology with endometriosis-related ovarian neoplasms (n=21) and ovarian endometrioma (n=262) at a single institution from April 2008 to April 2018. (bmj.com)
  • Pathology of human neoplasms. (springer.com)
  • We aimed to assess the Kras mutational status along the histological continuum from normal ovaries to the development of benign, borderline and malignant ovarian mucinous neoplasms. (oncotarget.com)
  • These results suggest a role for the NEU gene product in the physiology of benign ovarian surface epithelium and the neoplastic epithelium of preinvasive borderline and some invasively malignant adenocarcinomas. (elsevier.com)
  • The histological types of benign, malignant and related ovarian neoplasma have been studied on the material from 677 women of different ages. (clinicaloncology.com.ua)
  • Although the peculiar histological features originally described in 1896, many authors now tend to indiscriminately include any kind of ovarian metastatic malignancy under this definition. (ispub.com)
  • Increased expression of VEGF protein by immunohistochemistry has been associated with decreased disease free survival 18 versus 120 months in early stage epithelial ovarian cancers. (knowcancer.com)
  • Only 25% of ovarian cancers are detected in stage I due to its nonspecific early symptoms. (dokita.ng)
  • Amplification and overexpression of the HER-2/neu and c-myc oncogenes occur in a significant fraction of epithelial ovarian cancers. (dokita.ng)
  • Mutation of hep53 tumour suppressor gene occurs in approximately half of advanced (stage III/IV) ovarian cancers and in 15% of early (stage IA/IB) cases. (dokita.ng)
  • Endometrioid ovarian carcinomas differ from high-grade serous ovarian cancers at the mutational level. (bmj.com)
  • METHODS: Sera from 92 healthy individuals, 61 with benign adnexal masses, 12 patients with FIGO Stage I/II ovarian cancers, and 27 patients with FIGO Stage III/IV ovarian cancers were assayed for sIL-2R alpha by enzyme-linked immunosorbent assay and CA 125 by radioimmunoassay. (duke.edu)
  • Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. (amedeo.com)
  • Nevertheless the ovarian teratomas may be completely asymptomatic up to locally anatomic complications, metastatic aggressive disease or non- metastatic implants as gliomatosis , or endocrine disturbances as thyrotoxicosis, neuroendocrine tumour behaviour, etc.1-3 The signs and symptoms are the peak of an iceberg and the part under water varies considerably. (thefreedictionary.com)
  • Ovarian carcinomas are believed to arise de novo from surface epithelium, but the actual molecular pathogenesis is unknown. (nih.gov)
  • The ovarian surface epithelium is a modified mesothelial tissue which undergoes species-dependent morphogenetic events throughout life (1,2). (springer.com)
  • An autoradiographic study of the rabbit ovarian surface epithelium before and after ovulation. (springer.com)
  • Isolation and ultrastructure of rabbit ovarian mesothelium (surface epithelium). (springer.com)
  • Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. (springer.com)
  • Background: Mucinous cystic neoplasms of the pancreas are distinct entities with malignant potential, the vast majority occurring in middle aged women. (sages.org)
  • Conclusion: To our knowledge, this is the first report of an HIV + patient with a mucinous cystic neoplasm and robotic resection. (sages.org)
  • Thoracoabdominopelvic computer tomography was also performed and revealed two expansive, predominantly cystic masses in both adnexal areas (with 10x16x11 cm on the right and 4x4x5 cm on the left), with solid hyper-enhancing components, suggesting bilateral ovarian cystadenocarcinoma ( Figure 4 ). (scielo.br)
  • Cystic ovarian neoplasm? (healthtap.com)
  • Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas. (nih.gov)
  • The rarest (2-4 % of ovarian carcinomas) of the five major histotypes, their genomic landscape remains poorly described. (biomedcentral.com)
  • Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas. (amedeo.com)
  • Factors Associated With Management of Pediatric Ovarian Neoplasms. (cancer.gov)
  • Kras mutation is a common phenomenon in many human neoplasms. (oncotarget.com)
  • The current investigation emphasized the efficiency of immunohistochemistry (IHC) typing as a tool for a more precise characterization of the origin and differentiation of human neoplasms. (iranpath.org)
  • About 90% of all ovarian malignancies are of the epithelial cell type. (dokita.ng)
  • In stark contrast, ovarian neoplasms account for approximately 1% of all childhood malignancies with those affecting the epithelium being extraordinarily rare. (stanford.edu)
  • Hereditary nonpolyposis colorectal neoplasms associated with other malignancies, more commonly of ovarian or uterine origin. (bioportfolio.com)
  • Gynecologic malignancies are especially prone to be associated with primary neoplasms elsewhere. (bvsalud.org)
  • Linder D, McCaw BK, Hecht F. Parthenogenic origin of benign ovarian teratomas. (medscape.com)
  • Biology of ovarian neoplasia / edited by E. D. Murphy and W. G. Beamer. (who.int)
  • Treatment of epithelial ovarian neoplasia is based on stage and histology. (cancer.gov)
  • To describe the clinicopathological and immunohistochemical findings in four cases of uterine tumour resembling ovarian sex cord tumour (UTROSCT). (pubmedcentralcanada.ca)
  • In this study, we describe the clinicopathological features of four uterine neoplasms composed entirely of sex cord‐like elements ie UTROSCTs. (pubmedcentralcanada.ca)
  • Aromatase in human common epithelial ovarian neoplasms. (nii.ac.jp)
  • The histologic type of ovarian neoplasm does not appear to affect the rate of adnexal torsion. (nih.gov)
  • It is partially due to their low frequency that little is known about the overall incidence, histologic subtypes, optimal treatment strategies, and natural history of ovarian surface epithelial neoplasms in children. (stanford.edu)
  • Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: A 10-year study in a tertiary hospital of eastern India. (msjonline.org)
  • Hazard FK, Longacre TA: Ovarian surface epithelial neoplasms in the pediatric population: incidence, histologic subtype, and natural history. (cancer.gov)
  • Depending on the precise nature and severity of the condition, treatments for an ovarian neoplasm can include chemotherapy , hormone therapy, or surgical removal. (wisegeek.com)
  • Conservative surgery with or without appropriate adjuvant chemotherapy can be offered to young women with early-stage ovarian neoplasms who wish to preserve their fertility potential. (waocp.org)
  • Clinical correlation of the IHC results for the 72 Stage I-IV invasively malignant neoplasms revealed no statistically significant association of the intensity of NEU IHC staining with either relapse-free or overall survival. (elsevier.com)
  • Its clinical manifestations, imaging modalities, and gross features can mimic ovarian malignancy. (plexusmd.com)
  • Malignant Ovarian Neoplasms are a clinical spectrum that includes all neoplasms derived from abnormal proliferation of ovarian tissue (epithelial cells, stromal cells, and germ cells). (dokita.ng)
  • Ovarian reserve evaluation has been the focus of substantial clinical research for several years. (bioportfolio.com)
  • Use of immunohistochemical staining panel for characterisation of ovarian neoplasms. (bmj.com)
  • We have especially focused on the immunophenotype of these neoplasms and have undertaken an extensive immunohistochemical analysis, using markers of epithelial, myoid, sex cord and neuroendocrine lineage as well as hormone receptors. (pubmedcentralcanada.ca)
  • The aim of this study is to examine Her-2/neu gene amplification and protein overexpression in a spectrum of ovarian neoplasms using both immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) techniques that are FDA approved. (elsevier.com)
  • BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature. (amedeo.com)
  • Unlike in adults, such neoplasms generally originate from the germ-cell line. (elsevier.com)
  • Germ cell neoplasms of the testis. (medscape.com)
  • Conclusions The assessment of serum CA19-9, CEA, SLX, and LDH levels may be a useful tool in the preoperative evaluation to differentiate between endometriosis-related ovarian neoplasms and ovarian endometrioma. (bmj.com)
  • Objective: To estimate the association between serum levels of CA 125 and the degree of differentiation in primary ovarian neoplasms. (ufrgs.br)
  • left salpingo-oophorectomy was performed and an ovarian SLCT of intermediate differentiation was diagnosed. (elsevier.es)
  • An ovarian neoplasm is an abnormal growth located on or in the ovaries. (wisegeek.com)
  • A systematic investigation revealed a bilateral ovarian cystadenocarcinoma associated with visceral dissemination, likely associated with nose cutaneous metastasis. (scielo.br)
  • 28) US: Ultrasound Table 10: Relative values of gray scale USG alone and in combination with color and spectral Doppler in differentiating benign and malignant ovarian neoplasms USG Sensitivity Specificity PPV (%) (%) (%) Gray scale USG 70 72. (thefreedictionary.com)
  • A retrospective review of girls 2-21 years who presented for surgical management of an ovarian neoplasm across 10 children's hospitals between 2010 and 2016 was performed. (nih.gov)
  • Brief Answer: ovarian neoplasm, surgical removal required Detailed Answer: Hello mam, thanks for trusting health care magic. (healthcaremagic.com)
  • This retrospective, single institute study aimed to evaluate pregnancy and oncologic outcomes in reproductive-age Thai women with early-stage ovarian neoplasms undergoing conservative surgical treatment. (waocp.org)
  • Previous reports examining adnexal torsion suggested that benign ovarian neoplasms are more likely to undergo torsion than malignant ovarian neoplasms. (nih.gov)
  • Benign ovarian neoplasms had a 12.9-fold increased risk of undergoing adnexal torsion when compared with malignant ovarian neoplasms (95% confidence interval, 10.2 to 15.9). (nih.gov)
  • Laparoscopic treatment in a case of torsion of ovarian benign mature teratoma. (nih.gov)
  • The presence of an ovarian fibroma can cause ovarian torsion in some cases. (wikipedia.org)
  • Is routine appendectomy at the time of primary surgery for mucinous ovarian neoplasms beneficial? (thefreedictionary.com)
  • Primary appendiceal malignant neoplasms represent 0.5% of all gastrointestinal malignant neoplasms. (jaoa.org)
  • [ 8 ] The most likely primary factor driving the increase in testosterone secretion in PCOS is an increase in ovarian enzymatic activity involved in the synthesis of testosterone precursors. (medscape.com)